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INTRODUCTION 
 
THE IMMUNE SYSTEM 
The human immune system is an intricate system that serves to protect the body from 
invading organisms, prevent them from replicating or spreading and to remove them. There 
are physical barriers in place that is the first line of defence that physically prevent the 
organisms from entering, and these are the skin and the mucous membranes. If these barriers 
are breached, for instance through cuts or wounds in the skin or particles are inhaled and enter 
through mucosal surfaces in the nose or the mouth, the body has other methods to deal with 
this – the two-parted immune system, the innate and the adaptive immune system.  
The innate immune system is the first to respond as it will locate and recognize foreign 
particles and effector mechanisms will continue the procedure by killing and eliminating 
them. The effector mechanisms constitute effector cells that kill infected cells and engulf 
bacteria with the added support by a whole colony of serum proteins, named complement. 
These actions are the body’s natural response, and they attack foreign particles without 
specificity. This means when the particle has been labelled as foreign and dangerous, it is 
attacked.  
The next level of protection is from the adaptive immune system. As the name implies, this 
system is adaptive, taking in to consideration what it has encountered on previous occasions 
and using this knowledge to create memory. A very important group of cells from the 
adaptive immune system are lymphocytes, B lymphocytes and T lymphocytes. B-
lymphocytes express immunoglobulins on their surface and they can recognize and bind to 
foreign antigens. After binding to its antigens, several differentiation and maturation steps 
follow, usually involving T cells (T helper cells). This results in the B-cells giving rise to 
plasma cells that will secrete these immunoglobulins; termed antibodies. The next time the 
body is attacked by the same pathogen, the body remembers this, and the production of that 
specific antibody will start more rapidly. The sole purpose of B-cells is to induce the 
production of antibodies, while T-cells have different roles; all involving interaction with 
other cells. T-cell antigen receptors, or T-cell receptors as they are often called, recognize 
antigens that are presented to them through the help of antigen presenting glycoproteins 
known as Major Histocompatibility Complex, MHC, molecules.  
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If the innate immune system can not handle a foreign particle, it will try its best to fight it 
until the elements of the adaptive immune response starts working, and the white blood cells 
come in to action.   
 
HUMORAL IMMUNITY 
An immune response that is caused by antibodies and their actions is termed a humoral 
immune response. A B-cell that has not yet encountered an antigen it is called a mature B-cell 
and it produces membrane-bound immunoglobulins that act as a receptor for antigens. 
Development of B-cells includes several phases where different constituents of B-cell 
receptor are assembled. After assembly, each B-cell will express only one type of B-cell 
receptor, but which type will vary between cells. As an antigen binds to this receptor, the B-
cell differentiates in to a plasma cell, and begins to secrete antibodies. These antibodies are of 
the same specificity as that of the membrane-bound immunoglobulin. Production of 
antibodies is the only effector function B-cells have in the immune system and antibodies 
with a variety of different specificities can be produced. There are five classes of antibodies 
produced; IgA, IgD, IgE, IgG and IgM, which each will be discussed in more detail.  
 
ANTIBODY STRUCTURE 
Immunoglobulins are comprised of 4 polypeptide chains, two identical heavy chains and two 
identical light chains, and these are assembled as a Y (See figure 1). The heavy chains of an 
IgG molecule each weigh around 50 kilodalton and exist in five isotypes, Ȗ, , Į, İ and į1. The 
light chain weighs around 25 kDa and exists in two isoforms, Ȝ and ț, hence a total weight of 
around 150 kDa is the norm for a whole immunoglobulin. Each arm of the Y consists of a 
heavy and a light chain, while the stem of the Y consists of two heavy chains, and they are all 
linked through disulphide bonds. In order to create diversity between antibodies, the 
polypeptide chains have different amino acid sequences. These differences are found at the 
top of each of the Y arms, in the variable region. The variable region is also where the antigen 
binding sites are found, hence where the antibody will bind to the antigen, the Fab portion. 
The antigen binding site on one arm of the Y is identical to the other arm of the Y. The rest of 
the polypeptide chains – the lower half of the light chains and all of the heavy chains are 
known as the constant regions, as a low level of variation in amino acid sequences are found 
here. The protease papain will cleave an immunoglobulin in to different fragments; two 
fragments of Fab and one fragment crystalline (Fc) (see figure 1). The Fv portion is the 
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smallest fragment that can still bind an antigen. The Fc portion will bind to different Fc 
receptors for IgG, known as FcȖ receptors, FcȖR2-8.  
 
 
Figure 1: The protease papain will cleave an immunoglobulin in to different fragments; two 
fragment antigen binding (Fab) portions and one fragment crystalline (Fc). The Fab fragment 
can further be cleaved to Fv, the smallest fragments that can still bind to an antigen. Fv made 
by expression of relevant gene fragments are termed recombinant single-chain Fv, scFv 9. 
 
 
TYPES OF IMMUNOGLOBULINS 
Immunoglobulins, Ig, are divided in to 5 different isotypes, IgA, IgD, IgE, IgG and IgM, and 
they have different functions and are found in different areas of the body. Immunoglobins 
have carbohydrate moieties attached at different amino acids, found as conserved sites at both 
the Fc and the Fab portion. IgG only have its glycosylation site at asparagine 297 on the Fc 
part, whilst other types have several sights at different amino acids, located on both the Fc and 
the Fab portion. For three of the immunoglobulins, the Fab and Fc parts are linked by a 
flexible hinge region, these being IgA, IgD and IgG. IgE and IgM have a rigid Ig domain 
instead of the flexible hinge region1. Emphasis will be put on IgG, as this is the antibody that 
has been studied in this thesis, but the other isotypes will be described briefly. 
                      
IgG 
IgG is the most abundant antibody in lymph and blood, where it will circulate just like IgM. It 
can be divided in to four subclasses, IgG1, IgG2, IgG3 and IgG4. It is a smaller molecule than 
IgM, and can therefore enter extracellular spaces and reach tissues more easily than IgM. The 
four polypeptide chains are linked by disulphide bonds, and the hinge region connecting the 
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two heavy chains have various numbers of disulphide bonds, 2 for IgG1 and IgG4, 4 for IgG2 
and 11 for IgG3. This makes the hinge region of IgG3 exceptionally long (see figure 2)10. 
When IgG binds to an antigen, it can either activate the complement system as well as 
triggering phagocytes to eat the antigen-antibody complex11 or it can cross the placenta and 
provide a foetus with immune protection while that of the foetus’ is still insufficient12.  
There are four subclasses of IgG, IgG1, IgG2, IgG3 and IgG4 (see figure 2). IgG1 (9 mg/ml) 
and IgG2 (3 mg/ml) are most abundant in serum, followed by IgG3 (1 mg/ml) and IgG4 (0,5 
mg/ml). IgG1 and IgG3 are the two subclasses mainly involved in Fc-receptor interactions 
and capability of complement activation. IgG1 is the subclass with the strongest ability to 
opsonise particles, followed by IgG3, while IgG3 is the main activator of the complement 
system, followed by IgG1. Both IgG1 and IgG3 can sensitize cells for elimination by NK 
cells. All four subclasses can neutralize particles to the same degree. IgG3 has a half-life of 
only 1 week, whilst the other subclasses have a half-life of 3 weeks13. In the mutant IgG3-
R435H, where arginine at position 435 is exchanged with histidine, an increased half-life is 
seen, comparable to IgG114. 
 
Figure 2: A schematic model of the four IgG subclasses. The molecules are composed of four 
polypeptide chains, two identical heavy chains and two identical light chains connected with 
disulphide bonds10. 
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IgM 
After an antigen encounter, IgM is the first antibody that is produced during an immune 
response. Following secretion from B-cells, IgM antibodies are mainly found in blood and 
lymph15. IgM has a low affinity for all sorts of pathogens, including bacteria, virus and self-
antigens, which is crucial in the onset of an early immune response16,17. The immune response 
of IgM is not very strong; hence multiple binding sites for the antigens are necessary for an 
effective response. IgM can group together as pentamers, i.e. 5 IgM molecules bound 
together, and can therefore bind to 10 antigenic determinants at the same time15. IgM is also a 
potent activator of the complement system.  
 
IgD 
IgD is expressed together with IgM on the surface of B-cells before antigen stimulation, 
where it acts as a trans-membrane antigen receptor18.  IgD can also be secreted and seems to 
have some effect on mucosal secretion and on the cell surface of basophils and other innate 
effector cells, but its exact role is not well understood19,20.  
 
IgA 
IgA is the most abundant antibody isotype and most of it is exported across mucous 
membranes. While IgG dominates the systemic immune system, IgA dominates the humoral 
mucosal immunity21. IgA is synthesised and secreted on mucosal surfaces over the entire 
body, though the gastrointestinal tract is the most important site because of its area. This is a 
sensible location as the majority of antigens that are swallowed or inhaled will end up in the 
gastrointestinal tract. IgA can exist in two forms, monomeric IgA is mainly found in the 
bloodstream and dimeric IgA is transported across the epithelial border and found on mucosal 
surfaces, in the gut and in saliva, tears and other secretions22. IgA can therefore have different 
functional properties depending on location and molecular form23. Intestinal IgA antibodies 
can activate immune responses by high-affinity binding as well as low-affinity binding, giving 
an effective protection24. IgA seems to lack an ability to activate complement21. 
 
IgE 
IgE and IgG are antibody isotypes found exclusively in mammals and are located mainly in 
tissue, unlike the other immunoglobulin isotypes13. IgE is the main antibody involved in type 
I hypersensitivity reactions, manifesting itself as allergic reactions in the lower or upper 
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respiratory tract, gut, skin or eyes, or as anaphylactic shock – a life-threatening immune 
reaction25. In this type of reaction, allergens crosslink to IgE molecules, which again bind to 
the IgE receptor FcİRI. This receptor is a high affinity receptor situated on basophils and mast 
cells surfaces, and this interaction results in release of histamine and other local mediators, 
causing a strong inflammatory response26. Mast cells are found in all connective tissues, and 
even though the concentration of IgE in serum is very low and the half life is short (around 
2.5 days), the affinity of the receptors on mast cells is so high that a strong response is still 
seen25.  
 
GM TYPES OF IgG ANTIBODIES 
Immunoglobulin allotypes are antigenic determinants that are recognized by specific 
antibodies. In a given isotype, the polymorphism of the chain is determined by the amino 
acids and the composition of these will determine the allotype27. Allotypes are named based 
on the heavy or light chains on which they were found. For IgG, the allotypes expressed on 
the constant region of the heavy chain are named Gm (genetic marker), followed by the 
number of the subclass, together with the allotype number or letter; for instance G1m1 or 
G3m528. Gm allotypes are not found in IgG4, but are found in the other three IgG1 subclasses, 
and vary between different races29,30.  
 
 IgG EFFECTOR FUNCTIONS 
 
ADCC 
Antibody dependent cellular cytotoxicity is a process where antibodies cover the antigen by 
binding to it with their Fab portion while the Fc portion binds to FcȖR’s, causing a lytic 
attack31. ADCC is usually mediated by Natural Killer (NK) cells, but may also be mediated by 
neutrophils and eosinophils. 
NK cells are a subgroup of white blood cells and are classified as large granular lymphocytes. 
They are usually considered a part of the innate immune defence due to a lack of antigen-
specific cell surface receptors and their absence of sensitization requirements before 
expression32-34. NK cells play a major part in ADCC and they possess several receptors, both 
inhibitory and activating, that all binds to MHC class I molecules, MHC class I-like 
molecules and molecules unrelated to MHC35. When ADCC is initiated by NK cells, the low 
affinity FcȖRIIIa receptor (CD16) on NK cells bind to the Fc portion of antibodies bound to 
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the target cells. Upon this antibody-NK cell binding, NK cells release cytotoxic granules and 
cytokines like interferon Ȗ (IFN-Ȗ). These granules contain granzymes and perforin, and they 
enter through the target cell wall and cause apoptosis, cell death36. The activity of NK cells 
can be increased up to 10-fold by treatment with interleukin-2 (IL-2), a cytokine signalling 
molecule37. 
 
ADCML 
Antibody dependent complement-mediated lysis (ADCML) is a process where IgM or two or 
more IgG antibodies bind to the surface of target cells. This will activate complement through 
the binding of IgG to C1q, the first step in the complement cascade and eventually lead to 
lysis of the target cell. The ability to cause ADCML can be measured using NIP specific 
antibodies, sheep red blood cells (SRBC) that are labeled with radioactive chromium, 51Cr. 
The SRBC’s act as target cells and react with rabbit anti-SRBC Fab fragments that are 
conjugated with NIP. Complement serum is added and the degree of lysis is determined by 
the level of radioactivity emitted, measured in a gamma counter38. Changes in the Fc region of 
IgG affects ADCC and ADCML, as modifications in the IgG3 hinge region gave different 
results between the two routes39. An IgG3 molecule with a modified hinge region, reduced 
from 62 amino acids in the wild type to 15 amino acids caused a 10-times increase in 
ADCML activity40.  
 
OPSONOPHAGOCYTOSIS AND SERUM BACTERICIDAL ACTIVITY 
When IgG binds to a pathogen with the Fab portion, and the Fc portion binds to an FcR on a 
phagocyte, then the phagocyte engulfs the pathogen by phagocytosis. The antibody that binds 
to the pathogen in order to induce phagocytosis is termed opsonin; hence the whole process is 
termed opsonophagocytosis. Opsonophagocytic activity can be measured by using respiratory 
burst, RB, that takes place in the effector cell; the phagocyte, and is measured by a 
flowcytometer and termed OPA41,42. OPA has been used to measure effectiveness of vaccines 
by immunization with an outer membrane vesicle vaccine against Neisseria meningitidis43. 
Serum bactericidal activity (SBA) is measured by an SBA assay where antibodies and 
bacteria are mixed, and a complement source is added to agar plates. After over-night growth, 
colony forming units (CFU) are counted and the results showed as percentage CFU 
surviving41,44,45.   
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IgG Fc RECEPTORS 
Fc-receptors – FcR – are found on several cell types of the immune system. When antibodies 
bind to antigens in one end, and to an FcR in the other, powerful effector functions are 
activated. Fc-receptors that bind to IgG are termed FcȖR, and six isotypes of FcR are found in 
humans, named FcȖRI (CD64), FcȖRIIa (CD32A), FcȖRIIb (CD32B), FcȖRIIc (CD32C), 
FcȖRIIIa (CD16A) and FcȖRIIIb (CD16B)46.  
There are two main types of receptors, inhibitory and activating. The activating receptor 
contains immunoreceptor tyrosine based activation motifs (ITAM), while the inhibitory 
receptor contains immunoreceptor tyrosine based inhibitory motif (ITIM). These motifs are 
necessary to recruit proteins involved in triggering activating (ITAM) or inhibitory (ITIM) 
signalling proteins47. Both activating and inhibitory receptors can be found on the same cell, 
causing a regulation of the immune response. NK cells only express FcȖRIIIa– an activating 
receptor, while B cells only express FcȖRIIb – an inhibitory receptor. As some receptors have 
a higher affinity for some antibody isotypes than others, this will further tighten the regulation 
of the immune response48. The only inhibitory FcȖR is FcȖRIIb, the rest are activating.  
FcȖRI is a high affinity receptor, while the rest are all of low to medium affinity. FcȖRI binds 
IgG1 and IgG3 in humans at an affinity of 108-109 M-1. The low affinity of most of the FcȖR 
is necessary, as a high affinity would cause a high degree of non-specific activation of the 
immune system 47. The neonatal Fc receptor, FcRn, is an Fc receptor first thought to be 
predominantly involved in the transportation of IgG across the placenta49. It has since become 
clear that this is just one of a number of functions this receptor has. In addition to mediating 
passive transfer of IgG from mother to offspring, FcRn also regulates IgG and albumin 
concentrations, MHC class II presentation and movement of IgG from one compartment to 
the next50. The binding of albumin and IgG to FcRn is pH dependent and binding occurs at 
acidic pH, ideally at pH 5, and then the proteins dissociate at pH 7.4. IgG can therefore be 
transported from the gut to the bloodstream51. This relationship between FcRn and IgG and 
albumin can possibly be used therapeutically to change half-life of administered therapeutics 
or antigens or to ease transport of therapeutics through the mucosa49,52.  
 
DC-SIGN 
SIGN-R1 is a C-type lectin receptor found on splenic macrophages in mice that among other 
roles binds to sialylated IgG and mediates the anti-inflammatory effect. DC-SIGN is the 
human orthologue and found on human dendritic cells53. IgG that has Į-2,6 sialylation can 
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bind to DC-SIGN, cause an anti-inflammatory effect and reduce the affinity to FcȖR54. When 
the sialylation was Į-2,3-sialylated, this IgG binding to DC-SIGN did not occur, making Į-2,6 
sialylation essential for anti-inflammatory activity55. The interaction between sialylated Fc 
and DC-SIGN is thought to lead to an innate Th2 response by activation of IL-33 from the 
spleen, causing an anti-inflammatory response56. When the body is in a state of inflammation 
the level of sialylation should therefore be reduced, meaning that the body makes adjustments 
in order to obtain homeostasis, by up-regulating and down-regulating anti-inflammatory and 
pro-inflammatory antibodies. This again would indicate that IgG that cause ADCC and trigger 
inflammation should be without fucose and sialic acid, whilst anti-inflammatory IgG ideally 
should be sialic acid- and fucose-rich57.  
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THE COMPLEMENT SYSTEM 
The complement system is a complex, but highly important part of the innate immune 
response that eliminates microbes and participate in process including clearance of immune 
complexes, synapse maturation, tissue regeneration and lipid metabolism58. It is a cascade of 
events including more than 30 different serum proteins that are present in blood at all times; it 
can be activated in three different ways but will congregate at the same step; the cleavage of 
C3 in to fragments C3a and C3b, and the binding of C3b to the surface of the pathogen. The 
three different pathways are the classical pathway, the alternative pathway and the lectin 
pathway (see figure 3).    
 
 
Figure 3: The complement system with the three different pathways, classical, lectin and 
alternative59 
 
The classical pathway was the first to be discovered, and is sometimes termed the antibody-
dependent as it is initiated by the Fc portion of IgM or IgG. The first step in the classical 
complement pathway is triggered by an immune complex, formed by the binding of IgG or 
IgM to the surface of an antigen. This further binds to the complement component C1, 
consisting of one active protein, C1q, that binds to the immune complex, and two inactive 
proteins, C1r and C1s. The binding of the immune complex to C1q sets of a chain of events, 
with cleavage of C2 and C4, and the generation of C3 convertase C4b2a that cleaves C3. This 
sets of the rest of the cascade with proteins labelled up to C9 and in most cases eventually 
leads to the death of the pathogen59. The lectin pathway is triggered by mannose-binding 
 21 
lectins (MBL) and ficolins that are situated on the surface of microorganisms, and activate 
MBL-associated serine proteases that cleave C4 and C2, leading to formation of C3 
convertase C4b2a and follows the same path as the classical pathway from there60. The 
alternative pathway is activated by hydrolysis of C3 in plasma, and the hydrolysed product 
will bind to factor D, creating the C3 convertase, C3bBb, and from this point on joining the 
same path the rest of the cascade as the two other pathways61. 
 
IgG GLYCOSYLATION 
Glycan is a term for complex carbohydrates and can be attached to for instance proteins or 
lipids. In humans these are found in two versions, N-glycosylated or O-glycosylated. In N-
glycosylation, the glycans are attached to a nitrogen molecule situated on the amino acid 
asparagine, originating from a lipid-linked oligosaccharide precursor; LLO, synthesised in the 
endoplasmic reticulum, ER62. Then follows a number of assembling and processing steps, 
mainly taking place in the Golgi apparatus63. O-glycosylation is attached to one of two amino 
acids, threonine or serine and shows a greater diversity than N-glycosylation, but is only 
assembled, not processed63. Human IgG contain a single N-glycosylation site at asparagine 
297 on their heavy chains, located in the Fc-part of the IgG molecule; hence N-glycosylation 
will be described in more detail (see figure 4)64.  
 
Figure 4: Crystallisable image of IgG showing the carbohydrate moiety (in red colour) 
attached to asparagine 297 in the Fc region65 
 
Other immunoglobulins have other and occasionally several glycosylation sites for 
carbohydrate moieties. Normal polyclonal IgG molecules display 15-20 % N-linked 
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glycosylation in the variable regions where the majority of glycoforms have 2 galactoses66,67. 
There are three principal classes of N-glycans, oligomannose, hybrid and complex (See figure 
5)68. The oligomannose variant only has mannose residues attached to the core, while the 
complex type has to arms that start with N-acetylglycosamine attached to the core. The final 
variant is the hybrid where one arm only has mannose and there are one or two antennae on 
the other arm69. 
 
 
Figure 5: The three types of N-glycans, oligomannose, hybrid and complex68 
 
N-linked glycosylation occurs at the sequence Asn-X-Ser/Thr, with the glycan attaching to 
asparagine and where X can be any amino acid apart from proline. The first step in the 
assembly of N-glycosylation starts in the rough endoplasmic reticulum, involving the acceptor 
dolichol monophosphate and the sugar nucleotide donor uridine diphospho-N-
acetylglucosamine (UDP-GlcNAc). The main product of this first reaction is dolichol 
pyrophosphoryl-GlcNAc, serving as the precursor for the assembly of the lipid-linked 
oligosaccharide, LLO. A number of assembly steps follow that result in the LLO 
Glc3Man9GlcNAc2-P-P-dolichol. This LLO has 14 sugar residues and is the precursor for the 
biosynthesis of all eukaryotic N-glycans. Glc3Man9GlcNAc2-P-P-dolichol is transported to an 
asparagine residue in an emerging protein, catalysed by an oligosaccharyltransferase (OST) 
and a cascade of trimmings take place, starting with the removal of three glucose units by the 
enzymes glucosidase I and II in the lumen of the ER, steps  that are associated with protein 
folding70. Following this, one mannose is removed by the enzyme Į-mannosidase I, and the 
glycoprotein is transferred to the cis-Golgi apparatus, now comprising the formula 
Man8GlcNAc2Asn. Removal of GlcNAc2 by the enzyme GlcNAc-phosphotransferase leads to 
Man-6-P70. High mannose N-glycans can be converted to hybrid- or complex type N-glycans 
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in the Golgi, mannosidases in the Golgi remove mannose, and the resulting Man5GlcNAc2Asn 
is a substrate for a glycosyltransferase in the next steps of the biosynthesis of either hybrid- or 
complex type N-glycans, formed by N-acetylglucosaminyltransferase I and II (GlcNAc-T-1 
and GlcNAc-T-2) activity63. Further steps include removal of all but three mannoses, followed 
by the addition of combinations of GlcNAc, galactose and sialic acid. The addition of core-
fucose attached to the GlcNAc closest to asparagine 297 also occurs in some cases63. 
Carbohydrates can influence functional properties of immunoglobulins and the different 
carbohydrates may be combined to form several different glycoforms (see figure 6). 
Aglycosylated immunoglobulins have a shorter half-life, binds less well to FcȖR’s and 
activate complement less effectively than their carbohydrate containing counterparts71. The 
sugar moiety is attached to asparagine 297 and always comprises a back-bone consisting of 
two N-acetylglucosamines. This is followed by three mannoses which are bi-antennary and 
each of the mannoses has a second N-acetylglucosamine attached. The rest of the sugar 
moiety includes fucose, sialic acid and galactose in different combinations. Terminal sugars, 
such as core-fucose and sialic acid affect the binding to FcȖRIII, which again will have an 
effect on antibody dependent cellular cytotoxicity (ADCC). The absence of specific terminal 
sugars may also affect the interactions between the amino acids and the sugar residues on the 
Fc part of an IgG, both hydrophobic and hydrophilic, which again can have a large impact on 
the effector functions of the antibody72.  
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Figure 6: 20 glycoforms situated at asparagine 297 on the Fc portion of IgG antibodies. 
Others have been observed, but these are the primary glycoforms, and the varities analyzed in 
this thesis. 
 
GALACTOSE 
 Galactose is the first sugar added after the mannose and GlcNAc backbone, and is attached to 
the biantennary N-acetylglucosamine (GlcNAc) on IgG (See figure 6). The glycans can hence 
be split in three subsets, depending on the presence of galactose or not, and also how many 
galactoses are present, IgG-G0 (no galactose), IgG-G1 (1 galactose on one of the biantennary 
GlcNAc’s) or IgG-G2 (1 galactose on each of the biantennary GlcNAc’s)1. IgG-G0 is present 
in around 16 % of total human IgG glycan pools, IgG-G1 and IgG-G2 both in around 35 %. 
That leaves 14 % of the pool, which is made up of IgG-G1 and IgG-G2 that also contain sialic 
acid 73. A lack of galactosylated IgG is often seen in patients with rheumatoid arthritis 74,75. 
Pregnancy in rheumatoid arthritis sufferers can result in an increase in antibodies with 
galactose combined with a decrease in symptoms64,76.  A lack of fucose gives an increased 
ADCC, but galactose was previously not thought to affect ADCC, as no change in ADCC was 
seen upon removal of galactose in monoclonal human IgG1 or in CHO-produced IgG131,77. A 
slightly increased ADCC have been seen in highly galactosylated human IgG monoclonal Į-
D, but this effect was only minor78. Interestingly, mouse IgG1 with high content of galactose 
has recently been shown to hold anti-inflammatory activity by engaging the inhibitory 
FcȖRIIb, further elucidating the glycan importance for IgG function79. 
 
FUCOSE   
Fucose is a sugar attached to the first N-acetylglucosamine (GlcNAc) of the sugar moiety 
attached to asparagine 297 on IgG and is hence called core-fucose (See figure 6)74. Around 70 
% of total human serum IgG contains core-fucose73. The presence or absence of fucose has 
been shown to be of vital importance to ADCC, as a lack of core-fucose causes an up to 50-
fold increase in the binding to FcȖRIII, and this will further lead to an increase in ADCC31,80. 
When the immunomodulator swainsonine was added to mouse IgG2a antibodies, the ASN-
297 glycan moiety was removed, resulting in a decline in effector functions and FcR binding. 
The effector functions required to activate ADCC mediated by mouse spleen cells were 
however not affected81. This is however not the case for all cells, as when swainsonine was 
used on monoclonal IgG from hybridoma clones, this resulted in a marked reduction in 
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ADCC mediated by interferon-Ȗ activated human polymorphonuclear leukocytes82. When 
adding ȕ-1,4-N-acetylglucosaminyltransferase III to human embryonic kidney-EBV nuclear 
antigen cells, this led to an increased production of  a hybrid type IgG1 antibodies without 
fucose, termed Glyco-1. These antibodies caused the expected increase in ADCC, 10-fold in 
this case, by increased binding to FcȖRIIIa83. Producing antibodies without fucose by using Į-
1,6-fucosyltransferase (FUT8), but with three different oligosaccharides at ASN-297,a hybrid, 
a complex type and a high-mannose variant, gave different ADCC responses. The complex 
type bound strongest to FcȖRIIIa and hence mediated the strongest human PBMC-mediated 
ADCC. Then followed the high-mannose antibodies, and lastly the hybrid non-fucosylated 
IgG1 with the weakest FcȖRIIIa binding and the weakest ADCC84. NMR analysis of IgG 
produced in CHO (Chinese Hamster Ovary) cells with and without fucose showed similar 
structures, while crystal structure analysis did not. By using X-ray crystallography, a 
structural difference was found between fucosylated and a-fucosylated IgG around tyrosine 
296; and this difference was a water molecule. Fucosylated IgG1 had two water molecules, 
whilst a-fucosylated IgG had only one water molecule, and this seemed to cause a difference 
in the environment surrounding tyrosine 296, and this alteration could possibly influence the 
ADCC85. To determine how non-fucosylated antibodies exhibit their high ADCC activity in 
human whole blood, two types of Į-CD20 IgG1, one fucosylated and one non-fucosylated, 
were tested for their ability to bind to antigens on target cells and to FcR on effector cells. The 
two types of IgG competed for binding to target cell antigens, and binding of fucosylated 
IgG1 blocked the increase in ADCC otherwise seen by non-fucosylated IgG. On the effector 
side, the non-fucosylated IgG1 bound so strongly to FcȖRIIIa that plasma IgG could not 
compete for this binding. Plasma IgG could however almost entirely stop fucosylated IgG1 
from binding to FcȖIIIa. The non-fucosylated IgG used in therapy therefore causes higher 
ADCC by preventing plasma IgG from binding to FcȖRIIIa and also by avoiding antigen 
binding competition with fucosylated IgG86. A lack of fucose is seen in leukocyte adhesion 
deficiency, LAD II, where bloodgroup H and Lewis antigens have a lack of fucose. This 
causes recurrent infections, as well as growth and psychomotor retardation 87. Lack of 
fucosylation showed an increase in ADCC and FcȖRIIIa binding for all IgG subclasses 
compared to their fucosylated variants 88.  
  
SIALIC ACID 
Sialic acid is a sugar moiety attached to galactose, hence without the presence of galactose 
there can be no sialic acid (See figure 6). Intravenous immunoglobulin (IVIG) is often used as 
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a treatment for autoimmune diseases, such as immune thrombocytopenia (ITP) and 
Kawasaki’s Disease. The doses needed are very high, usually 1-2 gram/kg bodyweight once a 
day, meaning extremely large quantities must be administered 89. The presence of sialic acid 
causes a reduced affinity for subclass restricted FcȖR’s, and hence a decrease in cytotoxicity 
is seen74. Sialic acid is required as it causes an up-regulation of the inhibitory FcȖRIIb, which 
will lead to a higher level of FcȖRIII needed for inflammation caused by auto-antibodies90.  If 
sialic acid is responsible for the anti-inflammatory effect, that could explain the large doses 
needed, as less than 10 % of total IgG is sialic acid rich-IgG74,91. The human C-type lectin 
receptor DC-SIGN is found on human dendritic cells that when bound to Į-2,6-sialylated IgG 
elicit an anti-inflammatory effect and reduce affinity for FcȖR. This effect was not observed 
when using Į-2,3-sialylated IgG, making Į-2,6 sialylation essential for anti-inflammatory 
activity53,54. This anti-inflammatory effect seen after interaction between sialylated Fc and 
DC-SIGN is thought to lead to an innate Th2 response by activation of IL-33 from the 
spleen56. This up or down-regulation of anti- and pro-inflammatory antibodies could therefore 
be the body’s way of obtaining homeostasis57.  
 
 
 
 
IgG AND DISEASES RELEVANT TO THIS THESIS 
 
FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA 
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition where pregnant 
women develop antibodies against the fetus’ platelet antigens. These antigens are termed 
human platelet alloantigens (HPA). 6 bi-allelic forms exist, with 1A being the most common, 
followed by 1B92. Whether the allelic form 1A or 1B is generated depends on the gene 
encoding integrin ȕ3, as Leu33 generates 1A and Pro33 generates 1B93,94. In Caucasians, it is 
caused by passage of maternal anti-HPA 1A antibodies through the placenta 85 % of the 
cases, as the HPA 1A negative mothers become immunized during the pregnancy94. In most 
cases this does not lead to clinically significant bleeding, but it can also lead to minor 
bleedings such as petechial and in the worst cases to intracranial haemorrhage and 
subsequently death can occur95. FNAIT occurs in about 1 in 1000 of all live births and should 
be considered for any neonate suffering from unexplained thrombocytopenia92. Expression of 
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fetal glycoproteins on platelets takes place from 16 weeks gestation96. A HPA 1B mother only 
produces HPA 1A antibodies to a HPA 1A fetus in 10 % of the cases, with an increased risk if 
she carries the HLA-DRB3*0101 allele, occurring in 30 % of the population97. It may occur at 
the first pregnancy, but in many cases, the women have been pregnant before98.  
To diagnose FNAIT, blood samples from the parents are analysed using either MAIPA or RIP 
assays. Monoclonal Antibody-specific Immobilization of Platelet Antigens (MAIPA) is an 
enzyme immunoassay where monoclonal antibodies are used to identify the maternal 
alloantibodies with glycoprotein specificity, excluding all other antibodies99,100. 
Radioimmunoprecipitation (RIP) is an assay that uses radioisotopes to tag the glycoproteins 
and platelet targets, capturing the maternal alloantibodies on a solid phase, making it more 
complex and more expensive than MAIPA. By using these methods the maternal 
alloantibodies can be tested for incompatibility to the fetus and be somewhat quantitated99. 
Maternal and paternal phenotyping is done by PCR101. Screening for HPA 1A negative 
women is not routinely carried out, but in a study were 100 000 pregnant women were 
screened and interventions carried out where suitable, the number of severe cases were 
reduced to 3 out of 57 compared to 10 out of 51 in prospective studies. The 100 000 women 
had their blood analysed for anti-HPA 1a antibodies every four weeks and the women who 
were positive for these antibodies received HPA 1A negative platelets one or two days before 
delivery, which was carried out by caesarean section 2-4 weeks before term102. It is also 
important to measure anti-Human Leukocyte Antigens (HLA) antibodies, as these might 
interfere with diagnosis and management. Even without blood transfusion, anti-HLA 
antibodies may still develop in 20-30 % of pregnancies. Platelets express HLA class I 
antigens and this can cause FNAIT induced by anti-HLA antibodies103,104.  
Treatment of FNAIT includes administration of IVIG, (beginning at 24 weeks’ gestation if a 
previous infant was affected), corticosteroid treatment, fetal blood sampling and intrauterine 
platelet transfusion, and early delivery in some cases99,105. Post-natal management includes 
administration of IVIG to the infant, as well as HPA -1A negative donor platelet concentrates 
if available105.  
Correlations between the degree of symptoms and the level of anti-HPA 1A antibodies have 
been seen in several studies106-108. Anti-HPA 1A levels have been significantly higher in 
women giving birth to children with severe thrombocytopenia (platelet count of <50x109/L) 
compared to women giving birth to children who were moderately thrombolytic (platelet 
count between 50x109/L and 149x109/L) or normal platelet count (between 150x109/L and 
450x109/L)109. The effect of glycosylation on these antibodies was considered for the first 
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time by mass spectrometry analysis of sera from 9 women who all developed IgG1 
alloantibodies against the fetus’ HPA. The specific IgG1 antibodies showed decreased 
fucosylation and increased galactosylation and sialylation compared to total background IgG1 
antibodies. As decreased fucosylation is known to increase ADCC activity, glycosylation 
could affect the severity of the disease110.   
 
INFECTION PREVENTED BY VACCINES USED IN THIS THESIS 
 
MENINGOCOCCAL DISEASE 
Neisseria meningitidis is Gram-Negative diplococci that can be either encapsulated or 
uncapsulated and can cause meningitis and sepsis 111. Several serogroups have been 
determined based on their capsular polysaccharide and three serogroups account for at least 
90 % of all meningococcal disease, serogroup A, B and C112,113. The area where the disease is 
most widespread is in Africa, in what is termed the meningitis belt. This extends from 
Ethiopia to Senegal and the main serogroup seen in this area is A, followed by W-135, C and 
X 114. N.meningitidis can cause meningitis of both epidemic and sporadic nature, and the 
clinical presentation is in most cases bacterial meningitis, where haemorrhagical skin lesions, 
stiffness in the neck, sensitivity to light and fever is seen. Pneumonia and conjunctivitis are 
other symptoms that may be present111. Signs of sepsis; hypotension and organ failure may 
also be presenting symptoms. It is treated with antibiotics and a rapid onset of treatment is 
vital to decrease morbidity and mortality114.   
Different vaccines exist against the different serogroups, some with higher success rates than 
others. An outer membrane vesicle vaccine against meningococcal B disease was developed 
at the Norwegian Institute of Public Health in the late eighties115-117.  A similar vaccine has 
been developed in New Zealand, based on the work from Norway, but with an antigen more 
suitable to the New Zealand outbreaks118.  
 
PNEUMOCOCCAL DISEASE 
Streptococcus pneumoniae is a Gram-positive diplococci responsible for a vast array of 
infections, including sinusitis, otitis media and pneumonia (non-invasive) as well as 
meningitis and bacteremia (invasive). It is also the main bacteria causing community acquired 
pneumonia119. In the very young and in the elderly, the bacteria can cause severe morbidity 
and mortality120. S.pneumococci is also categorized according to its polysaccharide capsule, 
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and more than 90 different serogroups have been documented. Available vaccines include 23-
valent pneumococcal polysaccharide vaccines against the 23 most common serogroups, such 
as Pneumovax (Sanofi Pasteur MSD) and one 13-valent pneumococcal conjugated-
polysaccharide vaccine called Prevenar (Wyeth)119. Prevenar is in many countries part of the 
children’s vaccination regime, whilst Pneumovax is a polysaccharide vaccine used in adults. 
As the main subclass produced following immunization with a polysaccharide vaccine, such a 
vaccine would cause little effect in children under the age of 2 years as their immune system 
is not capable of producing IgG2 antibodies121.  
 
INFLUENZA 
Influenza is a viral infection with an incubation period of 1.5 to 3 days, but can be as long as 7 
days122. Symptoms include fever, chills, myalgia, headache and cough, usually lasting for one 
or two weeks. For the elderly, the very young and the immunocompromised patients it can be 
a serious matter with increased morbidity and mortality123,123,124. The influenza virus has two 
types of surface proteins, hemagglutinin (HA) and neuraminidase (NA), and the name of the 
virus will be determined by the subtypes of these surface proteins, hence the pandemic 
influenza of 2009 was of the H1N1 strain whilst the avian influenza virus was of the H5N1 
strain124,125. The virus changes slightly from one year to the next by antigenic drift, where 
point mutations in the viral RNA lead to new strains, hence a new seasonal influenza vaccine 
is made for each season125. The choice of strains used for the current year’s vaccine is based 
on which viruses circulate at the time and how they spread, as well as the protection level of 
the current vaccine strains126. The influenza vaccines are usually formulated with inactivated 
virus, consisting of three different virus strains, influenza A H1N1, influenza A H3N2 and 
influenza B, not subtyped124,125. Following an influenza vaccination, the antibodies produced 
against the hemagglutinin proteins provide the best protection, and the antibody response will 
typically be measurably after 2-4 weeks125. In the spring of 2009, a new influenza virus, 
H1N1, originated in Mexico and soon spread throughout the world. This virus originally came 
from swine, but was antigenically dissimilar to other H1N1 viruses from either man or 
swine122. A vaccine was produced with the strain A/California/7/2009, and later samples from 
pandemic H1N1 patients from all over the world were found to be similar to that strain125. 
This caused a mass vaccination, and in Norway the vaccine used was Pandemrix®, produced 
by GlaxoSmithKline, a split killed/inactivated antigen vaccine, based on A/California/7/2009, 
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containing squalene as an adjuvant127. About 40 % of the population in Norway received at 
least one dose of this vaccine128.  
 
VACCINES USED IN THIS THESIS 
There are currently several delivery routes available for vaccinations, mainly different forms 
of injections, oral or nasal. The vaccine types used in the volunteers in this experiment had 
antigens formulated as follows: inactivated influenza virus with adjuvant (pandemic 
influenza), inactivated influenza-virus without adjuvant (seasonal influenza), unconjugated 
polysaccharide (pneumococcal disease) and outer membrane vesicle (meningococcal disease). 
The pneumococcal vaccine induces a B-cell response, no T-cell response, and is hence not 
recommended for children under the age of 2 years, as their immune system is not developed 
enough to start a T-cell independent B-cell response129. The main subclass of antibodies 
produced from a polysaccharide vaccine is IgG2, unlike the other vaccines that mainly 
produce an IgG1 response129,130. The presence of an adjuvant in a vaccine can increase the 
antibody titer; hence a difference might be seen between the vaccine serum from volunteers 
receiving the pandemic influenza vaccine compared to the seasonal influenza vaccine131. The 
outer membrane vesicle (OMV) vaccine is another way of formulating vaccines and the 
pneumococcal vaccine used in this experiment is of such a type. OMVs are spherical lipid 
bilayer vesicle found in the outer membrane of gram negative bacteria. The outer membrane 
of Gram-negative bacteria consists of an outer layer with lipopolysaccharide and proteins and 
the inner layer of lipoproteins and phospholipids132. For use as a vaccine, the OMVs can be 
purified by centrifugation to remove any macroparticles causing contamination, cells and cell 
debris, and are then ultra-centrifuged to produce pellets133. An adjuvant is often added to 
enhance the response, for the vaccine used here aluminium hydroxide was used130. This may 
lead to a different glycosylation pattern compared to the others.     
 
VACCINE RESPONSE 
Vaccination is the most effective cost-benefit medical drug on the market, and ever since 
Edward Jenner used cowpox to prevent small pox infection in 1798, vaccines have saved 
millions of lives134,135. A robust IgG response is generally a hallmark of an effective vaccine 
against invasive pathogens. Hepatitis B, meningococcal disease, rubella, pneumococcal and 
influenza are amongst the infectious diseases that vaccines have been developed for136. A 
large portion of the elderly population and those that are immuno-compromised benefit each 
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year from the seasonal influenza vaccine, with an average of 500 000 in Norway being 
vaccinated each year, around 10 % of the population (personal communication, Kjersti 
Rydland, Norwegian Institute of Public Heath, Department of Vaccine delivery).  
The effectiveness of vaccines have been analyzed categorically137-139, while the impact of 
glycosylation is only just starting. The glycosylation pattern following vaccination have just 
been published and showed that IgG following influenza and tetanus vaccination had an 
increased level of sialic acid and galactose, while the total IgG in these patients were 
unaltered140. Changes in the glycosylation pattern over the time course of vaccination would 
thus greatly influence vaccine effect. Detailed analysis of change in glycosylation is therefore 
crucial for a more comprehensive understanding of vaccine immune protection. Information 
about the IgG glycosylation during vaccination could also expose possibilities for 
glycosylation manipulation in vaccine formulation and adjusting vaccine schedules in order to 
maximize vaccine protective effects. Combining this knowledge with biological tests may 
provide answers as to the effectiveness and functions of the antibodies, possibly indicating the 
most effective vaccination schedule.  
 
IgG MUTANTS RELEVANT TO EFFECTOR FUNCTIONS  
Recombinant monoclonal IgG antibodies are used to study structure-function relationships 
and also therapeutically as treatment for cancer and for diseases of the immune system141-147.  
Two methods can be used to produce recombinant antibodies, either transient gene expression 
(TGE) or stable gene expression (SGE)148. In SGE, the nucleic acids become part of the 
genome by the way they are introduced in to the cell, leading to long term expression. This 
process is however time consuming because tedious cloning procedures are necessary to 
isolate a stable and effective cell line. Transient transfection is simpler and quicker, though 
the DNA added is not becoming a part of the genome and the cell will thus only produce 
antibodies as long as there is DNA present, resulting in a short-term expression.  
HEK 293E, a human embryonic epithelial fibroblast cell line is often chosen to produce 
recombinant proteins such as antibodies. For permanent transfection, mouse cell lines such as 
NS-0 and J558L can be used. NS-0 is a mouse myeloma cell line with a high yield that does 
not secret neither light chains nor heavy chains, and is extensively used as fusion partner to 
produce mouse hybridoma cell lines149-152. J558L is mouse B myeloma cells that is unable to 
produce heavy chains, but produces a mouse Ȝ1 light chain153. 
Analysis of differences in glycosylation pattern between cell lines, transfection types and 
effect of point mutations in recombinant antibodies have been done to some degree, but not 
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extensively. Point mutations in different amino acids could for instance lead to changes in 
glycosylation which could affect effector functions. IgG3 produced in Chinese hamster ovary 
cells with certain amino acids replaced with alanine showed increasing galactosylation and 
sialylation, providing a possibility for specific modulation of immunoglobulin production to 
optimize treatments154. Glycosylation pattern from recombinant Į-NIP chimeric mouse-
human antibodies from J558L cells have been analyzed previously without showing great 
differences between IgG1 and IgG3, apart from glycoforms G0F and G2F. IgG2 showed a 
similar glycosylation pattern to IgG3 and IgG4 to IgG1155,155.  
 
MASS SPECTROMETRY 
Mass spectrometry is an analytical method used to determine molecular weight of both 
organic and inorganic compounds. The molecules are ionized and the ions are separated 
according to their mass to charge ratio, m/z. They can be detected either qualitatively or 
quantitatively, both according to their m/z and their abundance156. As the field of proteomics 
and genomics surge, the use of mass spectrometry is also on the up-rise, and hence a desire to 
develop faster and more accurate equipment follows157.    
There are several ways to ionize compounds and there is a wide variety of equipment 
available to separate and to detect the ions, and a description of the ionization method and 
equipment used in this thesis only is included. We used liquid chromatography coupled to an 
Orbitrap, using electrospray ionization, ESI. Formic acid is included in the mobile phases to 
aid ionization as the sample is let in through the sample inlet, usually a needle. It is 
transformed from the liquid phase to the gas phase by vaporization. This takes place at 
atmospheric pressure or vacuum, while everything from the ion source to the end takes place 
under high vacuum67,158-160. This is to allow the ions a chance to travel from one end of the 
instrument to the other without being hindered or colliding with air molecules. ESI is an 
accurate, soft ionization technique that is ideal for large and fragile molecules, can be used for 
proteins and carbohydrates and allows for ionization of molecules directly from solution159. 
As ESI allows for several charges, not only one like matrix-assisted laser 
desorption/ionization (MALDI), ESI-MS allows for molecular weight determination of 
proteins exceeding 100 000 Dalton in weight158. After the ionization step, the charged 
particles enter the mass analyser, where they are sorted according to their m/z. There are 
several mass analysers available; we have used ion trap and Orbitrap. Ion traps trap the ions 
within a field, detecting the unstable ions. Orbitrap is also an ion trap, but a constant 
electrostatic field is used to trap the ions161. 
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For our work, the mass spectrometer of choice has been the Orbitrap, coupled with Liquid 
Chromatography (LC) and Electron Spray Ionization (ESI); LC-ESI-Orbitrap. The Orbitrap 
traps the ions in an electrostatic field created by two electrodes, one axial central and one 
outer coaxial electrode. These two electrodes make the ions travel both around and up and 
down along the axial electrode (See figure 7). Ions of different mass-to-charge ratios will 
travel differently, and the ion image current is only possible as long as the ions keep travelling 
in a stable spatial pattern along the axial direction. The ion image current is collected and is 
converted by analogue to digital conversion and further processed through acquisition 
software. When coupled to an electrospray ion source, this provides a sensitive and accurate 
mass spectrometer157,161,162.   
 
Figure 7: The orbitrap mass analyzer. The arrow indicates where the ions are injected. R and 
z are cylindrical coordinates, and the stable ions move both around the central electrode, as 
well as in the direction of the Z. 157 
 
The final step is the detector, where the ion current is amplified, and the transmitted signal is 
converted to a mass spectrum. In a mass spectrum, the m/z values are shown, as well as the 
intensity, the molecular weight and the abundance. Using this information, a data system 
provides the user with detailed knowledge of which components are there and how much of 
each type are present156. For complex mixtures, multiple-stage mass spectrometry or tandem 
mass spectrometry can be used157.  
We have used two types of fragmentation, both collision induced dissociation (CID) and 
higher energy C-cell dissociation (HCD). For both types of fragmentation, the ions collide 
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with a neutral gas and kinetic energy is converted to internal energy, and as this internal 
energy is spread throughout the compound, the ions dissociate. HCD takes place in a specific 
designated collision cell outside of the mass analyser while CID takes place within the mass 
analyser. The fragments created after HCD are transferred back in to the mass analyser 
directly and higher dissociation energies can be used as the low-mass cut off seen with CID is 
avoided, enabling a wider range of fragmentation pathways. The time aspect is of importance 
as HCD fragmentation may take up to twice as long compared to CID fragmentation163,164. 
The two fragmentation methods have been compared, though the results are inconclusive, and 
there is hence no obvious choice of which method to use165. For our studies, both methods 
were used, but mainly CID. HCD is more suitable for glycan fragmentation, as the mass at 
m/z 204, HexNAc, often is lost when using CID. Creating, separating and detecting ions can 
be done in several different ways, and the different elements used can be combined in 
different ways. This leaves a large variety of choices for analysis, each with different 
strengths and weaknesses.   
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AIMS OF THE STUDY 
 
Immunoglobulin G, IgG, is the major serum immunoglobulin, responsible for recognizing, 
neutralizing and eliminating toxic antigens as well as pathogens. Carbohydrates situated on 
asparagine 297 on the Fc portion of the IgG molecule have a substantial impact on the 
effector functions of IgG. In particular are the carbohydrates galactose, fucose and sialic acid 
of interest, as galactose is required to activate C1q, the first step in activation of the 
complement system. A lack of fucose leads to an increase in antibody dependent cellular 
cytotoxicity, ADCC and the presence of sialic acid is thought to be the main reason for the 
anti-inflammatory effect seen with intravenous immunoglobulin. To increase our 
understanding of this carbohydrate influence further, we set out to investigate the IgG 
glycosylation pattern in different settings. We were interested in seeing what effect, if any, 
amino acid point mutations, harvest time and choice of cell line and type of transfection had 
on the glycosylation pattern, and combined this with biological tests (paper I). We continued 
to compare the glycosylation pattern of antibodies isolated from serum from volunteers 
receiving different vaccines, analysed from blood samples drawn at different time points after 
vaccination (paper II). And finally the glycosylation patterns seen in the condition fetal and 
neonatal alloimmune thrombocytopenia (FNAIT) were investigated, where pregnant women 
develop antibodies against the platelets of their fetus (paper III).  
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SUMMARY OF PUBLICATIONS 
 
PAPER I 
 
Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from 
transiently as well as permanently transfected cell lines 
 
The aim of this study was to analyze IgG1 and IgG3 wild type and mutants produced in cells 
by both transient and permanent transfection. IgG1 and IgG3 are the most protective IgG 
subclasses, and as their effector functions depend on the presence of a carbohydrate moiety at 
asparagine 297 in the Fc portion, detailed structural carbohydrate analysis is therefore crucial 
to better understand and exploit the protective potential. Recombinant wild type and mutant 
IgG1 and IgG3 antibodies produced from three cell lines were analyzed for their glycosylation 
profile by a newly developed isolation technique with a high resolution, sensitive LC-ESI-
Orbitrap method. We detected clear differences between IgG1 and IgG3 glycoforms, where 
IgG1 generally contained fucosylated glycoforms whilst IgG3 mainly were non-fucosylated. 
IgG1 glycoforms differed between two permanent transfected cell lines, NS-0 and J558L. 
Transiently transfected HEK 293E cells produced IgG with a simpler and less developed 
glycosylation structure at the late harvest compared to the early harvest. Some of the 
transiently transfected antibodies showed higher ADCML activity from the early harvest 
compared to the late harvest. Generally, the glycosylation pattern of the mutants tested, 
including a hinge truncate mutant of IgG3, did not differ significantly from the wild type IgG. 
The striking difference in glycosylation pattern of IgG1 compared to IgG3 therefore appears 
not to be due to the long hinge region of IgG3 (62 amino acids) relative to the IgG1 hinge 
region (15 amino acids).  
This work demonstrated that differences in glycosylation pattern are seen between IgG 
subclasses, between cell lines and with different harvest times, which can influence effector 
functions.  
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PAPER II 
 
Differences in glycosylation pattern of IgG subclasses induced by pneumococcal, 
meningococcal and two types of influenza vaccines  
 
The objective of this study was to analyze serum or plasma taken at different time points, 
from volunteers receiving different vaccines to establish the IgG glycosylation pattern and 
look for changes with time and differences between vaccines. As glycosylation is essential for 
IgG effector functions, detailed structural carbohydrate analysis is therefore crucial to better 
understand and exploit the protective potential. Four different vaccines were used, a 
pneumococcal capsule polysaccharide vaccine, a meningococcal outer membrane vesicle 
vaccine, a seasonal influenza vaccine and a pandemic influence vaccine. Antibodies against 
specific vaccine antigens were captured using microtiter wells coated with the individual 
vaccines and analyzed for their glycosylation profile by a high resolution, sensitive LC-ESI-
Orbitrap method. Following immunization, the IgG subclass dominating the response showed 
an increase in galactose. The level of sialic acid levels increased slightly with time for most 
vaccines, but a large increase in sialic acid, the hallmark for anti-inflammatory activity, was 
not observed, not even from serum collected up to a year after immunization. Fucose levels 
did increase for some vaccinees, but for the majority fucose was unaltered. The total 
background IgG glycosylation varied little with time, and hence the changes seen were caused 
by immunization. The minor IgG subclass response varied between vaccine formulations. The 
presence of an adjuvant in the pandemic influenza vaccine seemed to produce simpler and 
fewer glycoforms compared to the seasonal influenza vaccine. This work demonstrated that 
detailed IgG glycosylation pattern analysis might be a necessary step in addition to biological 
testing for optimizing vaccine development and strategies.  
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PAPER III 
 
A prominent lack of Fc-fucosylation of platelet alloantibodies in pregnancy 
 
In this study we considered the glycosylation pattern of IgG antibodies from pregnant women 
against human platelet antigens (HPA) of the fetus. This is termed fetal and neonatal 
alloimmune thrombocytopenia (FNAIT) and can result in various clinical scenarios, from 
asymptomatic to petechiae to major organ bleedings including intracranial haemorrhages. The 
N-glycans from the anti-HPA-1A IgG from 48 pregnant women were isolated and analysed to 
acquire more insight in to the pathogenesis. Fucose was of particular interest, as a lack of 
core-fucose can lead to a substantial increase in antibody dependent cellular cytotoxicity, 
ADCC. The specific IgG were analysed using mass spectrometry, and a slight increase in 
galactosylation was seen, whilst fucosylation was markedly decreased compared to the total 
IgG1 in the same patients. To ascertain whether this skewing towards non-fucosylated IgG 
antibodies was unique to FNAIT patients, N-glycans from anti-HLA antibodies formed after 
platelet transfusion (refractory thrombocytopenia) and antibodies against platelet glycoprotein 
IIb/IIIa from immune thrombocytopenia were also analysed, but the response was only seen 
in FNAIT patients.  
The study showed that the atypical fucosylation seen in anti-platelet responses can be related 
to the immune milieu defined by pregnancy or the specific stimulating antigen. This 
influences IgG effector functions, including ADCC activity and may have a profound effect 
on disease severity and prognosis of alloimmune-mediated reactions against fetal cells and 
tissues. 
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METHODOLOGICAL CONSIDERATIONS 
 
ANTIBODY GENE TRANSFECTION  
Two methods can be used when producing antibodies, either transient or permanent 
transfection of antibody genes, with both its advantages and disadvantages. Transient 
transfection is carried out by inserting DNA into the nucleus, but as it is not assimilated into 
the chromosomes, the cells will produce antibodies only as long as there is DNA left. 
Permanent transfection is carried out by inserting the DNA into the nucleus, but in this case it 
is assimilated into the chromosomal DNA, and can therefore produce antibodies as long as the 
cells live. Cells with permanent transfected DNA can therefore be frozen and thawed when 
more antibodies are required, whilst the transient transfected cells only provide short term 
production. On the other hand, production of antibodies following transient transfection gets 
started quickly and with large quantities of product, whilst achieving optimum production 
from permanent transfection is both time- and labor-consuming.  We have used antibodies 
from both types of transfection in this study, but only the transient transfection was carried 
out by us, the permanent transfected antibodies were already produced and kept frozen. 
Glycosylation studies of both transfection types provided excellent results (paper I).   
 
ANTIBODY CAPTURE BEFORE MS ANALYSIS  
The specific antibodies were isolated from microtiter plates coated with vaccine antigens 
(paper II). When antibody subclass typing and quantitation is carried out with microtiter plate 
for ELISA studies in our lab, the wash between incubations usually includes PBS/tween. As 
tween can interfere with mass spectrometry results, we avoided the use of this reagent and 
washed with either distilled water or with 1 M NaCl followed by distilled water.  
Other methods for isolation includes using protein A and protein G Sepharose on filter plates 
and using vacuum to elute the antibodies110. In our experiments, we attempted to use 
Whatman 96 well 350 ȝl UNIFILTER microplate as a way of eluting antibodies. As the plates 
would make a higher vaccine antigen concentration or protein A or G Sepharose 
concentration, assumptions were made that the concentration of eluted antibodies would be 
higher than when using microtiter plates. A few alterations were made to the manufacturer’s 
specifications, and briefly, the filters were saturated with vaccine antigen or protein A/G 
sepharose, the serum was added and incubated at room temperature, and formic acid was used 
to elute the antibodies. A Whatman UNIPLATE Collection Microplate was placed underneath 
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the filterplate, and centrifuged at 1000 G for 4 minutes to collect the eluted antibodies. The 
concentration of antibodies obtained was too low to analyze further, and this method was 
disregarded.    
 
 IN WELL TRYPSIN DIGESTION BEFORE MS ANALYSIS 
Trypsin digestion was carried out by overnight digestion (paper I, I and III). 120 ȝl of 50 mM 
ammonium bicarbonate buffer with 15 % acetonitrile was added to each well in the microtiter 
plates or to each NanoSep© device to obtain a basic pH value. The mixture was heated at 
80°C for 5 minutes followed by 30 seconds of sonication in a water bath to make sure the pH 
of the antibodies were thoroughly adjusted. Trypsin was added to each well and NanoSep© 
device, sonicated for a further 30 seconds, and left at 37°C degrees overnight. Overnight 
trypsin digestion is the preferred method of choice to ensure full enzymatic digestion has 
occurred166,167. 4 hour long digestion have also been used168.    
 
MASS SPECTROMETRY CONSIDERATIONS 
When studying IgG glycosylation using mass spectrometry, different apparatus can be used, 
but the common types are matrix-assisted laser desorption/ionization (MALDI)-MS/MS and 
different versions of ion traps such as the Orbitrap167,169,170. The work included in this thesis 
has been carried out using LC-MS-ESI Orbitrap for paper I and paper II, and using nano 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) coupled to an Esquire HCT 
ultra ESI-ion trap-MS for paper III. For paper I and III we have used CID fragmentation and 
for paper II we started out using HCD, but changed to CID fragmentation, and all samples 
were digested with trypsin overnight.   
Analysis can be carried out using whole glycoproteins, glycopeptides or only glycans that are 
chemically or enzymatically released. Proteolytic digestion, either in solution or in-gel, 
provides detailed glycan structural information providing an accurate representation of 
glycopeptides171,172. Liquid chromatography is usually combined with mass spectrometry and 
coupled with LC-electrospray ionization, like we have done in all three papers, 
chromatographic separation of the glycopeptides is done before MS analysis. C18-reverse 
phase HPLC is often used to achieve good chromatographic separation173.    
Quantitative proteomics can be done using stable isotope labeling or it can be done label-
free174. We have focused on label-free analysis, which again can be done using area under the 
curve (AUC) or signal intensity based on precursor ions, or by counting the number of 
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peptides assigned to a protein in an MS/MS experiment175. Label-free glycopeptide analysis is 
relatively straightforward, but a few features must be considered. Large retention times can 
cause overlap with peptides eluting at the same time, and if these have the same mass/charge 
ratio, it will not be possible to identify each peptide174. In our case, the glycopeptides from 
IgG2 and IgG3 have the same mass/charge ratio, and can hence not be differentiated between. 
For our vaccine response study (paper II), we overcame this by quantitating the sera first 
using ELISA. Based on which vaccine had caused the response, we found there to be either 
minute amounts of IgG3 compared to IgG2 (the pneumococcal vaccine), or vice versa (the 
other three vaccines), meaning the glycopeptides found could be assigned to the right IgG 
subclass based on the vaccine administered. For the total background IgG, we separated IgG2 
and IgG3 by using protein A and protein G columns. Differences in MS intensity and sample 
background noise were resolved by using albumin as a standard that was run before and after 
each sample sequence run. MS/MS scans were run for some samples to verify their identity. 
To compare different integration methods both the area of the peaks (AUC) and the signal 
intensity of average height were tried, but as these gave the same results, the two methods can 
be used interchangeably and the signal intensity of average height was used. Before the actual 
samples were analyzed, several test-runs were carried out to make sure the results were 
reproducible from one analysis to the next. Statistical analysis was carried out using the 
Friedman test to evaluate differences between the visits and the Wilcoxon test to evaluate 
differences between specific IgG and total background IgG, both with a p-value of ޒ0.05 
considered statistically significant.  
Spectral counting is another way of quantitating glycopeptides where the peptides present in 
higher abundance are fragmented and the MS/MS spectra will reflect the protein amount176. 
This method is used for comparing different samples, hence not suitable for IgG analysis 
where the amounts of different glycoforms in the same sample are compared to each other.     
Labeling the glycopeptides with stable isotopes is another way of quantitating the samples and 
is considered a precise and accurate method for quantitation. Isobaric tags can be used, 
isotope-coded tags and also incorporating the isotope labels in the actual amino acid in the 
cell culture are all ways this can be carried out177-179. The method is however expensive and 
requires special training, the number of samples in each experiment is limited and not all 
samples may be eligible for isotope labeling174. This method for quantitation was therefore 
not an option for our analysis.      
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MEASUREMENT OF EFFECTOR FUNCTIONS 
ADCC and ADCML are in vitro methods used to study the effector functions of antibodies by 
reflecting immunoreactions taking place in vivo (paper I). These are approaches that measure 
the ability of antibodies to bind to the target cells and achieve lysis, and the success of this is 
measured by the emitted radioactivity. In ADCML, human complement from a healthy donor 
is added as the effector cell source and IgG that are bound to the target cells can further bind 
to C1q, the globular heads that make up the first step in the complement cascade180. In ADCC, 
human mononuclear leukocytes from a healthy donor are used as effector cells and the 
antibodies bound to the target cells can interact with FcȖRs on for instance natural killer cells, 
resulting in both lysis and the release of effector cytokines181. The two methods measure the 
effector functions in different ways, as the ADCML only measure the interaction with 
complement receptors, while the ADCC measure the ability to achieve lysis through FcȖRIIIa. 
The results obtained from In vitro testing cannot be directly transferred to in vivo, as the 
settings for in vitro analysis are controlled in a whole different way compared to in vivo. It 
can however give a good indication of the mechanisms of action and the likely outcome 
following administration of for instance monoclonal antibodies. Both ADCC and ADCML 
have been studied in vitro, and the results have been used to give a representation of the in 
vivo activity for both vaccine design and monoclonal antibodies used in cancer182-184.  
 
 
HUMAN SERUM COLLECTED FOLLOWING IMMUNIZATION 
Blood was collected from the volunteers following vaccinations at several time points 
following vaccination, not only the typical day 0, day 30 and day 10 that have been presented 
for most vaccinees (paper II). Some vaccinees had serum from additional time points 
analyzed, but the trends were similar to the time points chosen for paper II and did therefore 
not give supplementary information. The time points close to day 30 were similar to day 30, 
and after about day 60, the trends were as day 100. For vaccinees receiving the pandemic 
influenza vaccine, three samples apart from day 0, day 30 and day 100 were analysed and 
included paper II. For these, an increase in galactose for seen in both IgG1 and IgG3 for two 
of the younger vaccinees, while a decrease in galactose was seen for IgG1 and IgG3 in one 
vaccine belonging to the 65+ group. No changes in fucose or sialic acid were seen at these 
very late time points, hence we feel that the analysis from day 0, day 30 and day 100 give a 
good representation of the changes in glycosylation following vaccination.  
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IgG SUBCLASS DETERMINATION 
The antibodies obtained from the vaccine response studies were quantitated using microtiter 
plates coated with vaccine antigen (paper II).  IgG subclass specific antibodies obtained from 
the WHO/International Union of Immunological Societies (IUIS) immunoglobulin 
Subcommittee, and this gave relative values of concentration. As we did not have specific 
antibodies for each vaccine, exact ȝg/ml concentrations could not be obtained, and the amount 
of one IgG subclass was compared to another. For the meningococcal antibodies, we had 
IgG1 and IgG3 directed towards the meningococcal antigen, and could therefore quantitate 
precisely in ȝg/ml.    
 
PROTEIN  A AND PROTEIN G COLUMNS WERE USED TO ISOLATE TOTAL 
BACKGROUND IgG  
When using mass spectrometry to determine glycosylation patterns, it is difficult to 
distinguish between the IgG2 and the IgG3 subclass, as the trypsin cuts the protein so that the 
remaining amino acids are identical, and therefore will result in the same mass to charge 
values on the mass spectrogram. For the recombinant antibodies (paper I), this was not a 
problem as they were IgG1 and IgG3. For the FNAIT samples (paper III), this was also not a 
problem as these are IgG1 antibodies. For the vaccine response antibodies (paper II), and 
especially the pneumococcal vaccine, that produces an IgG2 response, this caused problems. 
It did not matter for the specific IgG response, as ELISA quantitation studies showed 
negligible amounts of IgG3 compared to IgG2. It was however a problem for the total 
background IgG,  as we wanted to compared the specific IgG2 vaccine antibodies to the 
background IgG2 antibodies. This was solved by coupling together protein A (binding IgG1, 
IgG2 and IgG3) and protein G (binding all four IgG subclasses), and eluting the antibodies 
from each column. Several test runs were carried out where different amounts of serum 
samples were injected in to the columns and eluted, and the eluates were quantitated using 
ELISA methods. In this way, we found the amount that provided an accurate and clean 
separation of the different subclasses, without overloading the columns so that all of the IgG1, 
IgG2 and IgG4 antibodies bound to the protein A column, and only IgG3 antibodies were left 
to the transferred to the protein G column. The columns were then separated, and the 
antibodies eluted from each column and analyzed using mass spectrometry.   
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PATIENT SAMPLING FOR FETAL AND NEONATAL ALLOIMMUNE 
THROMBOCYTOPENIA (FNAIT)  
Anti-HPA-1A allo-antibodies were collected and diagnosed at three different locations, but 
the methods were the same and the criteria for selection were the same, hence these results are 
comparable. To compare the glycosylation pattern with other types of immune responses, 
such as IgG formed after platelet transfusion or after immunization against HLA in earlier 
pregnancies as well as autoantibodies from immune thrombocytopenia (ITP) patients. The 
analysis on the last patient groups were all done at one location, Sanquin in Amsterdam. The 
spread of these patient groups will provide a good indication of whether the glycosylation 
patterns observed are only seen in pregnancy, or also in other immune responses.   
 
PURIFICATION OF ANTI-PLATELET ANTIBODIES FROM SERUM  
Early on in the FNAIT studies, the HPA-1A specific allo-antibodies were captured using 
human platelets110. Even though the results were reproducible, the background signals could 
still be improved. Using plates already coated with GPIIb/IIa antigens to capture the HPA-1A 
specific allo-antibodies was deemed suitable, and the background signals were eliminated and 
the results even clearer (paper III). PAK12 from GTI Diagnostics, Waukesha, USA were 
used. As a negative control, blank wells were used. Formic acid was used to elute the 
antibodies, followed by drying of the eluates and overnight incubation with trypsin, similar to 
the methods used for the recombinant antibodies and the vaccine response antibodies (paper I 
and II). This way of capturing allo-antibodies improved sensitivity, eliminated background 
and simplified the procedure.   
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GENERAL DISCUSSION 
 
THE IMPORTANCE OF GLYCOSYLATION 
Glycosylation of proteins is the most common covalent modification occurring in living 
organisms185. An enormous variety of glycans is possible, both with regard to the amino acid 
they are attached to and the composition of the monosaccharides. This biological diversity 
stems from proteins being primary gene products and the glycans being secondary gene 
products. Methyl, acetyl or sulfate groups can attach covalently to the glycans, hence 
chemical diversity is also a factor to be considered. The biological variety makes 
glycosylation primarily species- and cell-specific186. The processing of the glycan moiety is a 
complex procedure involving numerous enzymes and systems, thus the possibilities for 
abnormalities and defects increase exponentially. A complete lack of N-glycans is lethal, but 
even diseases where only a single enzyme is lacking can be very debilitating187. N-
glycosylation of immunoglobulin G influence both structure and effector function 
immensely72,80,188,189. Glycosylation is associated with activities as far apart as participation in 
neurodegenerative diseases such as Parkinson’s Disease through sodium channel 
glycosylation to affecting the organic anion transporting polypeptides that regulate absorption, 
distribution, metabolism and excretion (ADME) of a variety of drugs and toxins190,191. Even 
the human pathogen Streptococcus pyogenes has understood the importance of glycosylation, 
as it secrets an enzyme, EndoS, that hydrolyzes the sugar moiety on human IgG and thereby 
reduces its ability to activate complement and bind to Fc-receptors, thereby improving its own 
bacterial survival in human blood192,193.  Glycosylation is therefore of immense importance 
for immunoglobulins, but can the information obtained from glycosylation profile analysis be 
used in a safe and efficient way to aid in predicting and manipulating these monosaccharides 
to aid in diagnosing and treating different immunological conditions, without interfering with 
other parts of IgG effector functions? When and where are they used and can the designed 
recombinant IgG antibodies be altered and used without problems? 
 
THERAPY AND DIAGNOSTICS 
Intravenous immunoglobulin (IVIG) has for long been administered as a treatment for various 
immunological conditions and the anti-inflammatory effect of IVIG is largely attributed to 
sialic acid55,194-197. IgG autoantibodies are substantial contributors to autoimmune diseases, 
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meaning that the same class of molecules that promote a disease can also be used to cure it, 
for instance idiopathic thrombocytopenic purpura, and this is termed the intravenous IgG 
paradox89. The results obtained from studies in mice or other model systems may not always 
be transferrable to humans, but as IVIG has been used clinically for over 30 years, the results 
from mice models can be reasonably compared with human studies, This is a great advantage 
when trying to  understand IVIG’s mechanisms of action198. Several recombinant antibody 
therapeutics (rMAbs) are on the market today, all of them of the IgG isotype and 
glycosylation has an enormous impact on their mechanisms of action. When using rMAbs, 
several results may be sought after; including neutralizing and killing of molecules and cells, 
inducing apoptosis or acting as an antagonist or agonist of cellular activity, but also delivering 
molecules199. Natural Killer (NK) cells express the receptor FcȖRIIIa, and this receptor is 
responsible for ADCC activity. The receptor exists in two isoforms, 158Val and 158 Phe, and 
the 158Val isoform has higher binding affinity for IgG1, and therefore a higher ADCC 
activity200,201. In accordance with this, the Į-CD20 chimeric IgG1 Rituxan was found to be 
more effective in treating follicular non-Hodgkin lymphoma in patients with the 158Val 
isoform compared to the 158Phe isoform202.  
Glycosylation is not only important for allo-immune diseases and the immune response; it can 
also affect other conditions. The majority of diseases involving glycosylation are hereditary, 
but a few are acquired. Congenital disorders of glycosylation (CDG) are a group of genetic 
autosomal recessive diseases involving an abnormal glycosylation of mainly N- and O-linked 
oligosaccharides, but also involve other types of glycosylation defects203. Abnormalities in 
glycosylation will have large clinical consequences, involving several organ systems, 
especially development of certain parts the brain, the nervous system, liver, eye-sight, the 
immune system as well as parts of the gastrointestinal system187. 
This abnormal glycosylation is caused by defects in one or more of the 21 enzymes involved 
in the synthesis of the glycan portion, or the way in which carbohydrates are added to either 
proteins or lipids187,204. CDG is confirmed by measuring transferrin, as transferrin has two 
sites for N-glycosylation, and healthy controls will usually have sialic acids attached to each 
site, while CDG type I patients usually have un-sialylated transferrin and type II patients have 
an altered glycan structure with the N-linked occupied glycosylation sites187. The clinical 
presentation of CDG type II usually includes more severe psychomotor retardation than type 
I, but usually fewer cases of neurological defects, though mutations often occur amongst 
glycosyltransferases187,203. CDG-1b is a type of CDG with low levels of mannose phosphatase 
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isomerase, and is one of few CDG that can be treated, as administration of 1g/kg/day of 
mannose is an effective treatment204.  
Some diseases involving glycosylation are acquired. Chronic alcoholics see an increase in di-
sialylated TRF, a human glycoprotein, whilst the tetra-sialylated TRF decreases and tumor-
associated antigens express a high level of carbohydrates that are being investigated for 
diagnostic value in certain types of cancer205. Haptoglobin is an acute-phase protein that often 
is seen at higher levels in different diseases and also portrays increased levels of fucose as 
well as changes in sialic acid, which could potential clinical markers206. Using HPLC, 
carbohydrate groups were determined for several diseases, and rheumatoid arthritis and 
juvenile chronic arthritis patients had mainly a-galactosylated structures, while ankylosing 
spondylitis and systemic lupus erythematosus patients mainly had di-galactosylated 
structures, indicating glycosylation alterations triggered by specific diseases 207.  When using 
electrophoresis analysis as a diagnostic and prognostic test, differences in glycosylation 
patterns between different autoimmune diseases were found208.   
In the condition fetal and neonatal alloimmune thrombocytopenia (FNAIT), a lack of fucose 
was seen in the specific HPA-1A antibodies for most of the volunteers tested, but not in their 
total IgG (Paper III). This alteration was not seen in patients with refractory 
thrombocytopenia or idiopathic thrombocytopenic purpura (ITP), even though they too are 
mediated by antibodies. This skewing of fucosylation has not been observed in other immune 
responses, and could possibly be due to the specific HPA-1A response, the anti-platelet 
response or the pregnancy milieu dominated by TH2, either alone or combined. During 
pregnancy, a shift occurs where levels of T helper 1 cells (TH1) are down-regulated and 
therefore also production of for instance IFN-Ȗ and IL-2, while T helper 2 cells (TH2) levels 
are up-regulated and production of cytokines, including IL-4 and IL-10 are increased 
consequently209 . When platelets are transfused, anti-HLA class I (Human leukocyte antigen) 
antibodies may be generated, making future platelet transfusions problematic210. In our 
studies, no significant changes were seen in the fucosylation of these antibodies (paper III).  
Levels of galactose change with age and in different diseases64,74-76. Patients developing anti-
HPA-1A allo-antibodies after pregnancies and anti-HLA-antibodies in patients receiving 
platelet transfusion displayed increased levels of galactose compared to total background IgG, 
an occurrence not observed previously (paper III).  Transport of IgG from mother to child is 
mainly mediated by the neonatal Fc-receptor FcRn and this receptor also regulates the half-
life of IgG52. In mice, the half-life of IgG is reduced if the amount of galactose is high, which 
again could affect the IgG transport between mother and child, even though Fc-glycosylation 
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not seems to influence the binding to FcRn211,212. As a-fucosylated IgG is more pro-
inflammatory, the increased level of galactose may counteract the effects of reduced fucose, 
indicating a tight regulation of the immune response in FNAIT. These increased levels of 
galactose also predispose the glycan moiety for augmented levels of sialic acid. The patient 
group in the FNAIT studies was too heterogeneous to correlate glycosylation patterns with 
disease severity, but is likely that a-fucosylated anti-HPA-1A antibodies increase platelet 
phagocytosis via increased binding to Fc-receptors, hence screening and monitoring of these 
antibodies could possibly be used for prevention and diagnosis. There are therefore numerous 
examples of the influence and involvement of glycosylation, and in all of these, extended 
knowledge of glycosylation patterns would be beneficial.  
 
ARE THERE COMPREHENSIVE DIFFERENCES IN ANTIBODY 
GLYCOSYLATION BETWEEN DISEASES, ISOTYPES AND ORIGIN? 
 
DIFFERENCES IN GLYCOSYLATION BETWEEN IMMUNOGLOBULIN ISOTYPES  
The glycosylation of IgG has been studied extensively over the last years but is not the only 
immunoglobulin isotype with influence from glycosylation in both structure and function. IgA 
displays both N- and O-glycosylation on the Fab and the Fc portion of the molecule213. In 
contrast to IgG, over 90 % of the IgA N-glycans are sialylated and the N-glycosylation sites 
of IgA are less constricted compared to the more confined IgG N-glycosylation sites. This 
more spacious arrangement could be the reason for the increased IgA sialylation and also the 
lack of a-galactosylated IgG often seen in pregnancy214. IgE portrays N-glycosylation and this 
glycosylation seems to affect both the structure and the function of IgE, as removing or 
increasing sialic acid levels affected binding to anti-IgE monoclonal antibodies. Some 
carbohydrates strengthened the binding to FcİRI and others masked epitope expression215,216. 
IgE is mainly involved in type I hypersensitivity reactions, manifesting itself as allergic 
reactions or as anaphylactic shock – a life-threatening immune reaction25. IgE has also been 
shown to cause delayed anaphylactic reactions by interacting with carbohydrate moieties in 
red meat, galactose-Į-1,3-galactose217. IgD seems to have one site for N-glycosylation on 
each heavy chain and with glycans at both Asn354 and Asn445, MBL binding to Asn354 is 
not possible because this has restricted accessibility due to the glycans at position Asn445218. 
IgM portrays N-glycosylation, and has three glycosylation sites for complex glycans, and two 
for oligomannose glycans. It is not possible for IgM to activate complement via the lectin 
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pathway, as once IgM has bound to an antigen, the glycans become unreachable by the IgM-
antigen complex219. Glycosylation can therefore affect all immunoglobulin isotypes, but as 
IgG is the main antibody involved in recognizing, neutralizing and killing toxic antigens and 
pathogens, and the current recombinant antibodies on the market for use in therapy are IgG, 
they have not been studied to the same extent as IgG.  
 
DIFFERENCES IN GLYCOSYLATION OF RECOMBINANT IgG1 AND IgG3 
COMPARED TO HUMAN SERUM IgG1 AND IgG3  
Analyzing recombinant IgG1 and IgG3 antibodies produced in various cell lines we found 
that mutations in one or more amino acids did not influence glycosylation pattern much 
compared to the respective IgG wild type (Paper I). However, the glycosylation pattern did 
vary considerably between IgG1 and IgG3 as the IgG3 antibodies all were non-fucosylated, 
whilst the IgG1 antibodies were fucosylated. When analyzing antibodies following 
immunization with different types of vaccines, the specific antibodies directed towards 
vaccine antigens did not show this distinction except for the IgG3 produced following 
immunization with the seasonal influenza vaccine (paper II). There could be several reasons 
for this. As the non-fucosylated IgG3 was only seen after immunization with the seasonal 
influenza vaccine, vaccine formulation must be taken into consideration. Two of the vaccines 
contained adjuvants and the third is a polysaccharide vaccine producing mainly an IgG2 
response. The pandemic influenza vaccine contained a squalene adjuvant, an important 
cholesterol precursor with squalene synthase catalysing its biosynthesis220. It has previously 
been shown that a squalene synthase inhibitor improved N-glycosylation in Congenital 
disorders of glycosylation221,222. This could possibly affect the N-glycosylation following 
vaccination. The meningococcal OMV vaccination also included an adjuvant, Al(OH)3, and 
although this adjuvant does not have contain synthase inhibitors like squalene does, as an 
adjuvant it could affect the degree of non-fucosylation for IgG3. The third vaccine is a 
polysaccharide vaccine that produces IgG2 as the main responding subclass, and as 
recombinant IgG2 was not included in the recombinant IgG analysis (paper I) and it showed 
similar profiles to main responding subclass from the other vaccines (paper II), we can 
assume that non-fucosylation would not be seen here.  
From a transfection point of view, both permanent and transient transfection were used and 
the different cell lines gave the same result regarding non-fucosylated IgG3, hence 
transfection in itself, or enzymes within the cells may give the answers to the lack of fucose 
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for IgG3. Fucosyltransferases are enzymes responsible for fucose being transferred from 
donor guanosine-diphosphate fucose to glycoproteins223. As our recombinant IgG1 contained 
fucose, the enzymes required were present, but distinguished between IgG subclass. 
Structurally, the main difference between IgG1 and IgG3 is the hinge region, with 15 amino 
acids for IgG1 and 62 amino acids for IgG3224,225. Analysing chimeric-human NP-antibodies 
for ADCC activity, IgG3 showed a stronger ADCC activity compared to IgG1226. ADCC is 
mainly activated through FcȖRIIIa and a 50-fold increase in receptor-binding was seen when 
fucose was removed, hence the non-fucosylated IgG3 we found (paper I) were consistent with 
IgG3’s stronger ADCC activity80,226. Mammalian cell lines used for production of 
recombinant antibodies possess intrinsic enzyme activity that is responsible for the core-
fucose227. In human tissue, fucosylation is usually a result of several different activities and 
several fucosyltransferases have been cloned228.   
In a subset of IgG plasma cells there was a difference in interaction with the cell adhesion 
molecules selectin, as the interaction with E-selectin was strong and P-selectin was weak. 
This corresponded to increased levels of Į1,2-fucosyltransferase-VII messenger RNA and 
down-regulation of 2 ȕ1-6-N-glucosaminyltransferase compared to B-cells229. Hence 
differences in fucosyltransferases have been seen between cells and could possibly explain the 
fucosylation differences between the recombinant IgG compared to the IgG antibodies 
produced after immunization. Whether cells possess some fucosyltransferases or fucosylases 
that are more active towards one IgG subclass compared to another is not known, but that 
could possibly explain the skewing towards non-fucosylation seen in the recombinant IgG3 
antibodies. A 50-fold increase in ADCC activity was seen in an Į-CD20 chimeric IgG1 when 
produced in rat hybridoma YB2/o cells compared to CHO cells. The expression of FUT8, 
required for fucosylation, was found to be much higher in CHO cells compared to YB2/o 
cells, resulting in a highly fucosylated Į-CD20 chimeric IgG1 when produced in CHO cells, 
leading to lower ADCC activity31. 
The sera from the FNAIT patients (paper III) generally showed a lack of fucose in HPA-1A 
specific IgG1 antibodies, a phenomenon that has not previously been described for this 
subclass. As the total IgG1 did not show this trend, it seems to be related to the pregnancy or 
possibly to specific platelet antigens.  Fc-glycosylation can be affected by various B-cell 
stimuli, as all-trans retinoic acid decreases galactose and sialic acid, while Fc-galactosylation 
has been increased and bisecting GlcNAc has been decreased by the TLR9 ligand CpG 
oligodeoxynucleotide and IL-21 and could hence also be an explanation230. This skewing 
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towards non-fucosylation has not been seen in other conditions, but that does not dismiss its 
existence. 
 
GLYCOSYLATION INDUCED AFTER IMMUNIZATION - HUMANS VS. MICE 
The IgG antibodies produced after immunization showed no distinct difference in level of 
fucosylation, apart from the IgG3 antibodies produced after immunization with the seasonal 
influenza, while the recombinant antibodies were non-fucosylated for IgG3. The carbohydrate 
distribution of the naturally occurring antibodies in the body show that sialic acid is found on 
1-3 % of total IgG antibodies, core-fucose in around 70 % and galactose in around 85 % of 
total human serum IgG54,73. Experiments in IgG mice have indicated that especially sialic acid 
is increasing very late in the immune response, compatible with the notion that IgG act anti-
inflammatory when the acute risk phase during infection is over. In an experiment where mice 
were pre-sensitized with sheep IgG and challenged with a nephrotoxic serum, NTS, 
sialylation for total IgG was reduced by 40 % and for specific anti-sheep IgG by 50-60 %74,74. 
This lead to the notion that an IgG immune response has two phases, one pro-inflammatory 
phase that is shown in the acute phase during infection and possibly also right after a primary 
vaccination. This pro-inflammatory IgG activity could be caused by a lack of core-fucose, 
favoring ADCC activity and phagocytosis89,89,197,197,231,231. Mice that were immunized with 
bovine serum albumin (BSA) resulted in anti-BSA titres with reduced levels of 
galactosylation, while increased fucosylation were seen after each ovalbumin 
immunizations232,232,233,233. The experiments this hypothesis is based on mainly are carried out 
in mice and not in humans; hence results from human immunizations are needed to clarify if a 
two-phase biological activity could be observed following immunization in humans as well.   
When humans were vaccinated, we did not observe a striking lack of IgG core-fucose shortly 
after immunization compared to later time points (paper II). We also did not observe a 
striking increase in terminal sialic acid late in the response for any of the vaccines used. 
Human IgG1 responses after influenza and tetanus vaccination have recently been reported, 
and the same lack of non-fucose in the beginning and increased sialic acid at later stages 
following vaccination were seen, but instead increased galactose and sialic acid shortly after 
vaccination was seen. When two doses of the same vaccine were administered and serum was 
collected 3-5 weeks after each dose, the levels of sialic acid did not change with time140,140. 
We see the same increase in sialic acid shortly after vaccination, but at later time points, the 
values vary from stable (pneumococcal IgG2), decreasing to pre-vaccination levels (seasonal 
influenza IgG1) or increasing with each booster dose (meningococcal IgG1) (paper II). We do 
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not disagree that IgG can have two-phases, a pro-inflammatory and an anti-inflammatory, but 
the basis of inducing and balancing these striking opposite IgGs may not be as straightforward 
for humans as it seems for mice. Even though the anti-inflammatory activity of sialic acid rich 
human IgG seems well documented, glycosylation may not be solely responsible for these 
two IgG variants. It has recently been shown that immune complexes containing galactose-
rich mouse IgG1 asserted anti-inflammatory properties by supporting the association of 
FcȖRIIb with dectin-179,79,140,234,234.  
 
MANIPULATION OF GLYCOSYLATION 
Į-L-fucosidase is an enzyme responsible for hydrolysis of fucose from glycoproteins, while 
fucosyltransferase is necessary for the addition of fucose to a carbohydrate moiety235,236. 
These types of enzymes might not be easily  manipulated, but Į-1,6-fucosyltransferase 
(FUT8) is an enzyme that has been removed successfully to produce FUT8 knockout mice, 
producing antibodies without fucose for effector function analysis, but removing FUT8 also 
led to down-regulation of growth factor receptors in these mice237. A-fucosylated antibodies 
results in a drastically increased ADCC, making them exceptionally pro-inflammatory80. 
When producing antibodies for use in therapy, a non-fucosylated structure is therefore 
desirable for protection, and different approaches can be used to achieve this. The first glyco-
engineered antibody to reach the market was mogamulizumab, marketed as Poteligeo© in 
Japan in 2012. This antibody is produced in FUT8 knock out CHO cells and therefore has 
enhanced ADCC activity by its lack of fucose238. Manipulating the N-glycosylation pathway 
in non-mammalian cells in to a non-fucosylation mammalian type is one way, inactivating the 
fucosylation pathway or interfering with enzymes or chemical synthesis to remove fucose are 
other methods227. When using Chinese Hamster Ovary (CHO) cells, the enzyme GDP-6-
deoxy-D-lyxo-4-hexulose reductase can disturb the fucosylation pathway and the produced 
antibody will be without fucose239. The removal of fucose caused in increase in ADCC 
activity not only for intact IgG, but also for Fc-fusion molecules, such as single-chain Fv 
connected to Fc (scFv-Fc)240. An engineered antibody produced in FUT8 knock out CHO 
cells consisting of the CH1 and the hinge region from IgG1 and the Fc portion from IgG3, 
with the COOH-terminal CH3 domain substituted with IgG1 to enable protein A binding, 
provided increased cytotoxicity through both ADCML and ADCC241. 
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Sialidase is an enzyme that hydrolyses sialic acid in glycoproteins and glycolipids242. 
Sialyltransferase on the other hand, can increase the expression of Į-2,6 sialic acid. cDNA of 
STA6Gal I (ȕ-galactosyl-Į-2,6 sialyltransferase) was cloned from CHO cells (even though not 
thought to be expressed endogenously in this cell line), expressed in E.coli and applied to a 
recombinant antibody. This lead to 70 % of the N-glycosylation being Į-2,6 sialylated, 
compared to no sialylation in the non-transfected line, easing production of sialic acid rich 
recombinant antibodies for therapy243. 
These modifications and manipulations must though be exercised with care to avoid 
uncontrollable immunogenicity. The basis of inducing and balancing pro- and an anti-
inflammatory IgG may be more complex than just glycosylation patterns. The role of sialic 
acid regarding the anti-inflammatory activity of human IgG seems well documented, but the 
other monosaccharides may also play a role, as shown in a resent paper where immune 
complexes with galactose-rich mouse IgG1 asserted anti-inflammatory properties by 
supporting the association of FcȖRIIB with dectin-179,234. This complexity has further been 
shown in mice infected with the yeast Cryptococcus neoformans. When monoclonal IgG1 
antibodies were administered, the result was acute lethal toxicity and cardiovascular collapse 
due to an increase in platelet activating factor, PAF. This was caused by a complex between 
C. neoformans glucuronoxylomannan and IgG1, though not seen with administration of 
IgG3244. On the other hand, pro-inflammatory responses were diminished and granulocyte 
production increased to clear the fungal infection when mice received IgG1 before a C. 
neoformans infection 245. Insufficient amount of antibodies may not cause the desired 
response, but excessive amounts may be counterproductive. Very high concentrations of 
antibodies on the capsule surface showed interference with oxidative killing of C. 
neoformans246. The same antibody may exhibit both pro- and anti-inflammatory properties 
depending upon the type of microbe, the state of infection and the amount of antibody. All 
these factors contribute to the existence of a more complex picture than one where 
glycosylation is the only foundation for the two-phase IgG. The majority of successful 
vaccines today mediate an effectiveness that is proportional to the amount of antibodies they 
induce, but these findings could indicate a possibility for vaccine failure by inducing a too 
high antibody response 247. Three different monoclonal antibodies against Streptococcus 
pneumoniae were analyzed in vitro and two of them were found to promote killing with 
different requirements regarding presence of components and host FcR. In vivo, on the other 
hand, all three antibodies promoted killing, and with different requirements regarding host 
receptors and components248. 
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Inhibiting or removing transferases can be used to reduce expression of certain sugar 
molecules. Mice lacking ST6Gal sialyltransferase, an enzyme responsible for the production 
of a trisaccharide that is the ligand for the lectin CD22, a glycoprotein involved in activation 
of B lymphocytes, were found to have reduced immune function as antibody production was 
diminished by reduced B- lymphocyte activation249.  Fluorinated analogues of fucose and 
sialic acid can cross the cell membrane to enter cells, metabolise to donors for inhibitors of 
these monosaccharides and prevent their expression on the surface of the cell. Reduced sialic 
acid and fucose expression on myeloid cells can prevent selectin binding and weaken 
leukocyte rolling250. This does require very accurate engineering to make sure that the 
analogues are taken up in only the specific target cells to avoid a defective immune system. 
Mice deficient in several types of fucosyltransferases involved in functionalization of the 
protective responses of selectin ligands in chronic inflammation and bacterial infections 
turned out to die quicker than wild type mice when infected with Mycobacterium 
tuberculosis251.    
Another way of altering the carbohydrate composition is by endoglycosidases. Streptococcus 
pyogenes is a pathogen in humans that cause infection and autoimmune diseases and it secrets 
an enzyme, EndoS that hydrolyzes the sugar moiety on human IgG.  EndoS hydrolysis may 
affect several IgG effector functions, such as no phagocytosis, no C3a deposition and hence 
no complement activation and decreased binding to FcȖRIIa and FcȖRIIb  and thereby 
improving its own bacterial survival in human blood192,193,252.  In a model of antibody-induced 
thrombocytopenia (ITP), platelet specific 6A6 antibodies were investigated, to see whether 
EndoS treatment would give different results in different IgG subclasses. 6A6-IgG1, 6A6-
IgG2a and 6A6-IgG2b were tested, as IgG3 have been found not to have any activity in this 
model. Whereas IgG1 and IgG2b showed a marked reduction in their ability to clear 
thrombocytes, IgG2a did not, implying that the remainder of the sugar moiety after EndoS 
treatment, one GlcNAc and possibly one fucose, was enough for this particular subclass to 
display functional activity253. All four human IgG subclasses were tested for binding to 
different FcȖRs before and after treatment with EndoS. IgG1 bound to FcȖRIIa and FcȖRIIb, 
but following EndoS treatment this binding had almost disappeared. This was not the case for 
IgG2, as untreated IgG2 bound less well to FcȖRIIa and FcȖRIIb than IgG2 treated with 
EndoS254. This shows that EndoS might not be suitable as a general medicinal treatment for 
infections, as all IgG subclasses are not affected. The mouse IgG subclasses 1, 2a, 2b and 3 
were tested against a lactate dehydrogenase-elevating virus (LDV), and IgG2a proved the 
strongest response, by delaying onset and progression more than the other 3 subclasses255. A 
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similar result had previously been seen for panel of virus, including mouse hepatitis virus 
(MHV, A59 strain), pneumonia virus of mice (PVM, strain 15) and Mengo virus (C50L 
strain)256. As the entire panel of IgG subclasses are not incapacitated by EndoS, the likelihood 
of opportunistic infections could be reduced if EndoS was used as an immunosuppressant 
compared to more traditional treatments. On the other hand, if EndoS was to be used as 
treatment of autoimmune conditions, the lack of response from some subclasses could also 
lead to a failed therapy as not all subclasses would respond253.  
 
DIFFERENCES IN GLYCOSYLATION BETWEEN CELL TYPES 
The recombinant antibodies on the market today are produced in either Chinese hamster ovary 
cells or one of two mouse cell lines, NS-0 or Sp2/0199. CHO cells and human cells have a very 
similar way of making glycoforms, but there are some differences. A main difference is that 
CHO cells do not possess the enzyme N-acetylglucosaminyltransferase-III(GnTIII) that is 
needed to produce bisecting GlcNAc257,258. As the levels of bisecting GlcNAc in human IgG 
generally do not exceed 10 % of total IgG, it might not be expected to have a great effect on 
bioactivity259. However, when the levels of bisecting GlcNAc in a chimeric mouse/human Į-
CD20 IgG1 antibody reached 48-71 % of total IgG through co-expression of GnTIII in CHO 
cells, this caused an increase in ADCC activity. More specifically, a 10-20 fold lowering of 
the concentration of antibodies required for ADCC through their higher affinity for FcȖRIII 
were observed, as the effect was blocked by an Į-FcȖRIII antibody. The Į-CD20 antibody 
used here was licenced for treatment of non-Hodgkin’s lymphoma, meaning a lower dose 
could be administered without a reduction in effect188. Rituximab and trastuzumab are two 
recombinant monoclonal IgG1 antibodies used therapeutically for the treatment of Non-
Hodgkin’s lymphoma and rheumatoid arthritis, and breast cancer, respectively. Addition of a 
bisecting GlcNAc and removal of a terminal ȕ1,4-linked galactose were the changes made to 
alter their carbohydrate composition, and it was carried out by a soluble recombinant rat ȕ-
1,4-N-acetylglucosaminyltransferase III (rGnTIII), produced in baculovirus-infected insect 
cells. The addition of bisecting GlcNAc caused a 10-fold increase in ADCC, while a lack of 
galactose caused a 3-fold decrease in ADCML260.  
Another major difference is sialic acid. In human IgG, Į-2,6-linked sialic acid is seen, while 
CHO cells produce Į-2,3-linked sialic acid261. This does also represent a large percentage of 
total IgG, as human IgG usually have less than 1-3 % sialic acid54. Sialic acid is however 
important for an antibody’s anti-inflammatory properties, and this needs to be Į-2,6-linked 
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sialic acid, so a recombinant IgG used as a therapeutic agent produced in CHO cells may 
therefore not provide the same anti-inflammatory properties as human IgG would54,74. 
The rMAB cetuximab is produced in NS-0 cells and has low levels of sialic acid and terminal 
galactose found in the Fab region, termed the gal epitope262. As it is common to possess anti-
gal antibodies, this should not cause huge disturbance in the body, but hypersensitivity and 
IgE antibodies against cetuximab have been observed, though the anti-gal epitope antibodies 
were present in the serum before therapy started for the majority of patients263,264, and as a 
result of this, NS-0 cells may not be considered an appropriate cell line for rMAB production. 
CHO cells do not seem to have this problem with gal epitope expression; though a single 
report has shown that 20 % of human CD4 produced in CHO cells carried the gal epitope265.  
By the addition of different enzymes, glycosylation can be altered by adding or removing a 
specific carbohydrate, such as FUT8 (Į1,6-fucosyltransferase, an enzyme needed to produce 
fucose) knock-out mice or by using specific conditions for the cells to grow in266. Mouse-
human chimeric IgG1 antibodies expressed in Chinese Hamster Ovary (CHO) cells where 
defects have been inserted in to the biosynthesis of the carbohydrates were grown to 
determine whether changes in the glycosylation would cause a change in functional 
properties267. The cell lines used were Lec-1 CHO (high mannose intermediate attached), Lec-
2 CHO (sialic acid attached) and Lec-8 CHO (galactose attached). The antibodies produced in 
Lec-1 cells had difficulties binding to C1q and activating complement, had a reduced half-life, 
and showed a lowered affinity for FcȖRI receptors. Antibodies from both Lec-2 and Lec-8, 
showed no difference in affinity for FcȖRI receptors, in vivo half-life, ability to activate 
complement lysis or complement activation measured by ELISA267,268.  
A monoclonal human IgG1, Campath-1H, was stripped of its carbohydrate moiety, leading to 
abolishment of ADCC and complement lysis activity. When removing only sialic acid, no 
change in IgG activity was seen.By removal of sialic acid and most of the galactose, a 
reduction in complement lysis activity was observed, but ADCC was not affected77. Point 
mutations in IgG where different amino acids were exchanged for alanine caused an increase 
in galactosylation and sialylation compared to wild type IgG154. Sodium butyrate can affect 
gene expression, and when added to the cell culture of CHO-K1 cells, an increase in the 
amount of human chimeric antibodies was seen, while the glycosylation profile remained the 
same. High concentrations of sodium butyrate can give different apoptotic responses in 
different cell lines, as 2 mM butyrate killed NS-0 cells within 24 hours, whilst CHO cells 
could survive for at least a month longer at the same concentration, as long as fresh medium 
was supplied every two days269.  
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Tetracycline in culture medium is another way of engineering glycosylation pattern, as an 
increased concentration of tetracycline can cause over-expression of glycosyltransferases, 
leading to growth inhibition and cell toxicity. The right amount of tetracycline can however 
increase the bisecting GlcNAc glycoforms, thought to influence ADCC270.   
To conclude; increased expression of GlcNAc and removal of fucose to lead to an increase in 
ADCC activity, while an increase in sialic acid enhances an anti-inflammatory effect, a 
function that has also recently been seen with galactose74,79,80,91,188,260. Increased knowledge 
about glycosylation patterns and its consequences for the immune response, combined with 
the ability to alter the carbohydrate composition can be used to control the therapeutic use of 
these antibodies in a safe manner. 
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Abstract 
The effector functions of IgG depend on the presence of carbohydrates attached to asparagine 
297 in the Fc portion. In this report, glycosylation profiles of recombinant wild type and 
mutant IgG1 and IgG3 antibodies produced from three cell lines were analyzed using LC-
ESI-Orbitrap.  Clear differences were detected between IgG1 and IgG3 glycoforms, where 
IgG1 generally contained fucosylated glycoforms whilst IgG3 mainly were non-fucosylated. 
When using NS-0 and J558L cells for permanent transfection, IgG1 wt glycoforms differed 
between the two cell lines, while IgG3 wt glycoforms did not. Transiently transfected HEK 
293E cells were used to produce IgG1 and IgG3 wt and mutants, affecting complement 
activation. Cell supernatants were harvested at early and late time points and analyzed 
separately. IgG’s harvested late showed simpler and less developed glycosylation structure 
compared to those harvested early. The IgG harvested early were slightly more effective in 
complement activation than those harvested late, while the antibody dependent cell-mediated 
cytotoxicity was unaltered. Generally, the glycosylation pattern of the mutants tested, 
including a hinge truncate mutant of IgG3, did not differ significantly from the wild type 
IgG’s. The striking difference in glycosylation pattern of IgG1 compared to IgG3 therefore 
appears not to be due to the long hinge region of IgG3 (62 amino acids) relative to the IgG1 
hinge region (15 amino acids). Furthermore, mutation variants at or near the C1q binding site 
showed similar glycosylation structure and difference in their complement activation activity 
observed earlier is thus most likely due to differences in protein structure only.   
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Introduction 
 
IgG is the major serum immunoglobulin and is responsible for recognizing, neutralizing and 
eliminating toxic antigens as well as pathogens [1]. IgG is divided in four subclasses, IgG1, 
IgG2, IgG3 and IgG4, with specific and overlapping roles in immune protection, where IgG1 
and IgG3 are generally the most important subclasses involved in interaction with Fc-
receptors as well as in the capability of activation of the complement system and thereby 
inactivate or kill the pathogen [2-9].  
Carbohydrate groups attached to asparagine 297 in the Fc-portion of IgG have a direct 
influence on the effector functions of the molecules [10;11].  Recombinant monoclonal IgG 
antibodies are used to study structure-function relationships and also therapeutically for 
treatment of cancer and diseases of the immune system, and establishing their glycosylation 
pattern will therefore be of interest [12-19]. The field of glycosylation analysis of 
recombinant IgG antibodies described in the literature is very limited and motivated us to 
undertake the present study. 
The carbohydrate molecules attached at asparagine 297 are mannose, ȕ-N-acetylglucosamine 
(GlcNAc), galactose, fucose and sialic acid, and emphasis will be put on the last three in this 
report. Each of these three carbohydrates affects the immune system and the immune response 
in different ways. A high degree of galactosylation of IgG is associated with improvement of 
symptoms during pregnancy for particular auto-immune patients [1;20-25]. Fucose is present 
as core-fucose and a lack of fucose causes increased antibody-dependent cellular cytotoxicity 
(ADCC) [1;26]. Sialic acid is believed to be responsible for the anti-inflammatory effect of 
Intravenous immunoglobulin (IVIg), often used to treat autoimmune diseases [1;27-29]. 
Without any carbohydrates; IgG has a shorter half-life than monomeric a-glycosylated IgG. 
IgG without carbohydrates bind less well to FcȖR’s and activate complement less effectively 
than their carbohydrate containing counterparts [9;20;30].  
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When producing recombinant antibodies either transient gene expression (TGE) or stable 
gene expression (SGE) is used [31]. The antibodies studied in this paper are produced using 
both types of expression systems in order to evaluate possible differences in IgG 
glycosylation pattern by the two procedures. The cell lines used are HEK 293E, NS-0 and 
H558L. HEK 293E is a human embryonic epithelial fibroblast cell line broadly used to 
produce recombinant proteins, including antibodies [32]. J558L is mouse B myeloma cells 
that is unable to produce heavy chains, but produces a mouse Ȝ1 light chain [33]. NS-0 is a 
mouse myeloma cell line that does not secret neither light chains nor heavy chains, and is 
extensively used as fusion partner to produce mouse hybridoma cell lines [34-36].  
 
The glycosylation patterns of human serum have previously been determined and both IgG1 
and IgG3 displayed heavily fucosylated glycoforms [24]. Recombinant Į-NIP chimeric 
mouse-human antibodies from J558L cells have been analyzed previously, and the 
glycosylation pattern did not show great differences between IgG1 and IgG3, apart from a 
few glycoforms. IgG2 showed a similar profile to IgG3 while IgG4 was closer to IgG1 [37]. 
When IgG3 produced in Chinese hamster ovary cells had certain amino acids replaced with 
alanine, an increase in galactose and sialic acid was observed, providing a possibility for 
specific modulation of immunoglobulin production to optimize treatments [38]. Apart from 
this, to our knowledge we found no reports of comparisons of recombinant IgG glycosylation 
regarding subclass, point mutations, cell lines or transfection type.  
We captured IgG1 and IgG3 wild types and mutant molecules by a novel microtiter plate 
method and analysed the glycoforms by using mass spectrometry analysis of in-well trypsin 
liberated glycopeptides. The mutant antibodies were produced using HEK 293E cells and two 
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different times of harvest were used to study possible variations in glycosylation over time 
during transient transfection.   
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Materials and methods:  
 
Transient transfection  
10 different IgG1 and IgG3 variants were tested from two different harvest times. This 
included 6 IgG1 variants; IgG1 wild type, and 5 mutations, IgG1 L234A, IgG1 L235A, IgG1 
P329A, IgG1 D270A and IgG1 L234A/L235A. For IgG3, we tested 4 variants; IgG3 wild 
type, IgG3 m15 (the hinge region had been shortened from 62 amino acids to 15), IgG3 
D270A and IgG3 P329Al, (see table 1). All the mutations were done using PCR, and the 
DNA fragments were introduced to the vector. The vector was co-transfected to into the HEK 
293E cell line, and the supernatant collected to carry out the tests as previously described 
[39]. In this report, the naïve HEK 293E cells used were thawed, transfected and cultivated, 
and the supernatant was collected at different times, an early collection and a later collection 
were used, the early collection being 4 days after the transfection and the later collection 10 
days after the transfection.  
In addition, a further two mutants from HEK 293E cells were tested, but these had been 
harvested only once on a previous occasion before they were frozen. These were IgG1 H435A 
and IgG3 N297A (See table 1). 
   
Permanent transfection 
A further 6 variants of IgG1 and IgG3’s were analyzed (see table 1). These cells were 
transfected earlier, the supernatant collected, and the cells and supernatant have been kept 
frozen in liquid nitrogen for several years, they were therefore not freshly harvested for this 
exact experiment. 
 
Antibody preparations 
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We used either purified antibody preparations isolated as previously described [39] or 
unpurified cell growth supernatants. 
 
Antibody capture before MS analysis  
We used NIP specific antibodies in this study, and could therefore use microtiter plates coated 
with NIP16BSA to capture the antibodies. Briefly, 100 l PBS pH 7.3 containing 1 g/ml 
NIP16BSA were added to the microtiter wells and left for at least 48 hours at 4°C, and then 
washed 4 times with 300 l distilled water. 300 l blocking buffer (1 % dried milk powder in 
PBS/azid) was added to each well, and left to incubate for 1 hour at 37°C. The plate was 
washed 4 times with distilled water, and 100 l of each antibody preparation was added in 
each well, in duplicates. The 10 antibody samples from HEK 293E cells were provided as cell 
supernatant, and 100 ȝl contained around 1.5 ȝg/ml from the first harvest, and between 0,8 
and 2.6 ȝg/ml from the second. The other samples were diluted so 100 ȝl contained 
approximately 30 ȝg antibody. This was incubated for 2 hours in 37°C to allow antigen-
antibody binding. The plate was then emptied, and washed with 300 l 1 M NaCl 3 times, and 
twice with 300 l distilled water. Following the last wash, the plate was knocked vigorously 
against a bench covered in cell paper, to remove any remaining water. The plate was sealed 
with tape and refrigerated until trypsin digestion was started.   
 
 In well trypsin digestion before MS analysis 
120 l Trypsin digestion buffer (50 mM ammonium bicarbonate with 15 % acetonitrile) was 
added to each well, incubated for 5 minutes at 80°C and sonicated in a water bath for 30 
seconds. 30 l 50 mM ammonium bicarbonate containing 600 ng of trypsin in 30 (Sequencing 
grade modified trypsin from Promega (V5111) or Roche (11418025001)) was added to each 
well, sonicated for 30 seconds in a water bath and then incubated over night at 37°C. The 
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content of the wells were transferred to Eppendorf tubes (Rainin LiteTouchTM 1,7 ml 
Microcentrifuge Tube LTT-170_B(17011862)), and dried in a Speedvac centrifuge (Maxi dry 
Iyo F.D.1.0, Heto-Holten, Allerød, Denmark) which took approximately 2 hours. 17 l of 
0.1% formic acid was added to each tube, quickly centrifuged, sonicated for 30 seconds, 
centrifuged at 16 000 G for 10 minutes at 4°C, and 15 l transferred to MS tubes (VWR 
International microvials PP, 0.3 ml with short thread, Cat. No 548-0440 and VWR 
International Screw cap PP transparent, 9 mm silic.white/PTFE r, Cat.No. 548-0034), and the 
tubes were consequently stored at -20°C until they were analyzed.  
 
Mass spectrometry analysis of trypsin digested IgG samples 
The samples were analyzed on a LC-ESI-Orbitrap. LC separation was carried out on Agilent 
1200 series capillary high-performance liquid chromatography (HPLC).  
6 l injected in to reverse phase (C18) nano online liquid chromatography coupled MS/MS 
analysis, length 150 mm and width 0.075 mm, GlycproSIL C18-80 Å, Glycpromass, Stove, 
Germany. The peptides were eluted in positive ion mode and CID mode (collision-induced 
dissociation), where the spectra are isolated and detected in a linear ion trap, providing speed 
and sensitivity.  
Mobile phases were A: water with 0.1 % formic acid and B: acetonitrile with 0.1 % formic 
acid. LC separation was carried out with a gradient from 10 to 95%, with a flow rate of 0.2 
l/min. 
LC system connected to nanoelectrospray source of ThermaScientific LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany) operated by Xcalibur 2.0.  
Nanospray ionization was carried out by applying 1.2 kV between 8 m diameter emitter 
(PicoTip Emitter, New Objective, Woburn, MA). The capillary temperature was 200°C and 
capillary voltage was 30 V. 
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Mass spectrometry data analysis 
Mass spectrometric data were analyzed using Thermo Scientific Xcalibur software version 
2.0. The mass tolerance of the parent ion was set at 5 ppm. The MS peaks from each 
glycopeptides were extracted as the maximum peak height within the same retention time 
window based on parent ion mass, and the MS/MS spectra were manually searched using 
Qual Browser version 2.0.7. The transiently transfected antibodies with two harvests were all 
done in duplicates and the permanently transfected and the transiently transfected with one 
harvest only were analyzed once. Standard deviation was calculated as STDAV in Microsoft 
Excel 2010. Before the actual samples were analyzed, several test-runs were carried out to 
make sure the results were reproducible from on analysis to the next.  
 
Measurement of effector functions. 
Antibody dependent complement mediated cell lysis (ADCML) and antibody dependent cell 
mediated cell lysis (ADCC) were measured as previously described [39;40]. Briefly, Cr51 
labeled sheep red blood cells (SRBC) sensitized with rabbit Fab anti-SRBC conjugated with 
NIP were used as target cells both for ADCML and ADCC. The supernatants were harvested 
with a harvesting device (Skatron, Norway) and the radioactivity is measured using a gamma 
counter and the lytic activity is calculated.   
 The liberation of radioactivity coincided with effector activity. Human serum was used as 
complement source as previously described and human peripheral blood lymphocytes were 
used as effector cells for ADCC. 
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Results 
 
 
The 18 recombinant IgG molecules studied in this report were all analyzed using LC-ESI 
Orbitrap, searching for 20 different glycoforms [24;41]. The 20 glycoforms were searched for 
based on the mass of the remaining peptide plus the carbohydrate moiety (see figure 1). The 
glycoforms can be in different charge states generated during the MS analysis, depending on 
the number of protons they have, charge state 2 (M+2H)2+, when two protons are added, and 
charge state 3 (M+3H)3+, when three protons are added. Even higher charge states are 
available, but not detected in the experiments reported here. The peaks were integrated and 
the values for each glycoform in charge state 2 and 3 were combined (see table 2), and the 
values for all glycoforms added together, and from this the percentage distribution of each 
glycoform was calculated. A spectrum for IgG1 D270A harvest 1 shows the relative 
distribution before integration of four of the main glycoforms (see figure 2). Glycoforms that 
only were present in less than 1.0 % were excluded from the graphs for ease of presentation.   
 
Transient transfection: IgG1 molecules contain strikingly more fucose than IgG3 
molecules:  
A clear difference between IgG1 and IgG3 glycoforms was detected. IgG1 wild type and 
mutants all show rather similar glycoforms and IgG3 wild type and mutants all showed rather 
similar glycoforms, but these two profiles were opposite to each other, with IgG3 variants 
having non-fucosylated glycoforms (see figure 3, figure 4 and table 3).  
 
Early harvest at transient transfection contained more complex glycoforms than the late 
harvest:  
IgG1 wild type and mutants and IgG3 wild type and mutants all showed rather similar profiles 
within the subclass in the early harvest, and the same is seen in the late harvest, though with a 
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decrease in the more complex glycoforms and from IgG1 D270A standing out with more G2F 
than any of the others (See table 3, figure 3 and figure 4). In the late harvest, wild type and 
mutants again show a rather similar pattern to each other, but with less complex glycoforms 
compared to the early harvest (see figure 3). A few stood out in the early harvest, as IgG1 
D270A displayed more G2F than any other IgG1, and IgG3D270A also contains a small 
amount of glycoform G1F, while the presence of G1 was slightly higher in IgG3wt and 
IgG3D270A (see table 3, figure 3 and figure 4). 
 
Choice of cell line for permanent transfection influences glycosylation pattern for IgG1, 
but not for IgG3 
A further 6 wild types and mutant IgG1 and IgG3’s were analyzed, 2 IgG1 and 4 IgG3 (see 
table 4). The two IgG1 variants differ in their glycoforms, in that chimeric IgG1 from J558L 
cells hardly has any of the G0F glycoform but a lot of G2F and the exact opposite are seen for 
chimeric IgG1 from NS-0.  The amount of G0 and the presence of G2 also separate the two 
(see figure 5). 
The four IgG3 antibodies from permanently transfected cell lines show similar glycosylation 
profiles, with only two glycoforms being present, G1 and G2 (see table 4 and figure 6A). 
Three of the antibodies show a very similar percentage distribution of these two glycoforms, 
while the last antibody, IgG3 wild type Į-NIP from J558L deviates from this.  
 
Transient and permanent transfection affects glycosylation pattern of both IgG1 and 
IgG3:  
Chimeric IgG1 chimer from NS-0 portrays a glycosylation profile with a similar trend 
compared to the other transiently transfected immunoglobulins from harvest 1 (see table 3 and 
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table 4). Chimeric IgG1 from J558L on the other hand, has a completely different profile, 
with G2F as the main glycoform.   
IgG3 wild types and IgG3 m15 from transiently transfected HEK 293E cells had equal 
amounts of G1 and G2 in the first harvest, but mainly G1 in the late harvest, while IgG3 wild 
type NS-0 and IgG3 m15 NS-0 have G2 as their main glycoform (see figure 6B). Similarities 
are seen between mutants of different transfection form, such as IgG3 wild type Į-NIP J558L 
and IgG3 wild type from NS-0, and IgG3 m15 R435H from NS-0 and IgG3 m15 from NS-0 
(see figure 6B). IgG3 glycoforms isolated from NS-0 and J558L are therefore rather similar, 
but differ from the ones produced by HEK 293E cells. 
 
Some of the transiently transfected IgG mutants from the early harvest displayed higher 
complement mediated lysis compared to IgG’s from the late harvest  
All 10 transiently transfected antibodies from two harvests and the 6 permanently transfected 
antibodies were tested using ADCML, and some were also tested using ADCC.   
ADCML analysis for the 10 transiently transfected antibodies showed that IgG1 P329A, IgG3 
P329A and IgG1 L234A/L235A had very low or no cytotoxic activity. IgG1 wild type, IgG3 
wild type, IgG3 D270A and IgG3 m15 all gave showed good activity, but with very little 
variance between the two harvests. IgG1 D270A, IgG1 L234A and IgG1 L235A all showed 
higher cytotoxic index for the early harvest compared to the late harvest, hence a more active 
effector function was seen (see figure 7A and 7B). 
When the permanently transfected antibodies were tested for ADCML activity, they all gave a 
high response that did not seem influenced by the choice of cell line. Both chimeric IgG1 Į-
NIP and IgG3 wild type produced in NS-0 cells showed similar results to their J558L- 
produced counterparts. The two IgG3 m15 variants, IgG3 m15 and IgG3 m15 R435H, both 
from NS-0 cells also gave similar results (see figure 7C). 
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IgG1 D270A, IgG1 L234A and IgG1 L235A were also tested for ADCC activity and did not 
show any significant difference between early and late harvest (data not shown). 
 
IgG1 H435A and IgG3 N297A from transiently transfected HEK 293E cells – one 
harvest only 
Two more mutants were transiently transfected from HEK 293E, but these had only been 
harvested once and then frozen, IgG3 N297A and IgG1 H435A. IgG3 N297A did not contain 
any glycoforms, as would be expected, as 297 is the position where the sugar moiety is 
attached.     
IgG1 H435A portrays a quite similar pattern to IgG1 chimeric from NS-0 with regards to the 
major glycoforms (see table 4 and figure 6B). 
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Discussion:  
It has lately been accepted that the structure of carbohydrates attached to asparagine 297 in 
the Fc portion of the IgG molecule has a profound influence on effector functions and thus 
immune protective capacity. The study of the variation of the glycosylation pattern of 
recombinant IgG antibodies is therefore important for a more comprehensive understanding 
of the relationship between structure and function as DNA-based construction of antibodies is 
becoming the fastest growing therapeutic category in the pharmaceutical industry. The aim of 
our study was to reveal possible variation in glycosylation patterns related to differences in 
subclasses, point mutations, hinge truncation, host cell line, permanent versus transient 
transfection and the time of harvest for transient transfection. We chose to study IgG1 and 
IgG3 as they are generally the most immune protective human subclasses. The recombinant 
antibodies used in this study were chimeric, mouse V-region and human C-region constructed 
molecules containing a full mouse Ȝ-1 light chain. Although not formally documented in the 
literature, it is highly unlikely that neither the V-region nor the light chain will influence the 
glycosylation structure at position N297 in the Fc-region of IgG and thus our choice of 
recombinant antibodies anticipate to reflect glycosylation of fully human IgG under the same 
conditions.  
Several striking observations came out of the present study. First of all there was a clear 
difference in the glycosylation pattern of recombinant human IgG1 and IgG3, revealed by 
using three different cell lines as host for the production and by using permanent and transient 
transfection of IgG coding DNA vectors. The most striking difference was a predominant 
presence of fucosylated glycoforms in IgG1, while IgG3 was mainly non-fucosylated (see 
figure 3 and figure 4). Observations of human serum IgG did not portray the same trend, as 
IgG3 did not show this lack of fucose [24]. Similar glycosylation structure analysis of the 
same IgG1 and IgG3 NIP-antibodies produced from J558L cells has been performed in some 
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old studies, but with conflicting results compared to ours. In that analysis, the glycosylation 
pattern did not show great differences between IgG1 and IgG3, apart from a few glycoforms 
[37]. They did not detect this heavily fucosylation of IgG1 and non-fucosylation of IgG3. The 
reason for this is not obvious, but might be due to a different analytical procedure used then, 
and our state of the art mass spectrometry equipment, giving rise to more accurate and 
sensitive analysis.  
The differences in glycosylation pattern of IgG1 and IgG3 we observed could possibly be due 
to a very large hinge region of IgG3 (62 amino acids) compared to IgG1 with a hinge of 15 
amino [42;43]. This was apparently not the case as the hinge truncated mutant IgG3m15 
containing only one of the hinge exons coding for 15 amino acids exhibits essentially the 
same glycosylation pattern as wild type IgG3, (See figure 4) [44]. Furthermore, the IgG3 m15 
mutant has an enhanced ADCML activity compared to IgG3 wt [45]. The reason for this is 
not obvious and a possible explanation could be due to an altered glycosylation profile of 
IgG3 m15. We addressed that question in this report and have clearly shown no major 
difference in glycosylation structure which can explain the extraordinary high ADCML 
activity of IgG3 m15. 
Secondly, the time of harvest seemed to impact glycosylation.  The antibodies produced in 
transiently transfected cell lines that were harvested 4 days after transfection showed more 
complex glycoforms compared to the antibodies harvested at 10 days after transfection.  
Similar observations have been seen previously, as Chinese Hamster Ovary (GS-CHO) cells 
producing chimeric IgG4 monoclonal antibody cB72.3 showed increasingly shorter chained 
and simpler glycoforms with increasing growth period [46]. This could possibly be attributed 
to the different enzymes involved in the glycosylation being put under more strenuous 
pressure, and not functioning as well as in the beginning of the production, leading to 
uncompleted sugar composition [46]. When we tested the antibodies for ADCML activity, we 
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observed a general trend of higher activity in the early harvest compared to the late harvest 
(see figure 7A and 7B). Thus the more short-chained carbohydrates observed in the late 
harvest seem to depress ADCML activity, while this was not the case for ADCC which was 
unaltered between the two harvests. Apparently C1q binding or C1 activation demand more 
extended carbohydrates to be effective. ADCC, on the other hand seems more independent of 
this carbohydrate structure variation. 
Thirdly, it was clear that choice of permanent cell line affected the glycosylation, as NS-0 and 
J558L caused different glycosylation profiles for IgG1, while no major differences were seen 
for IgG3 (see figure 5 and figure 6A). Monoclonal chimeric mouse/human IgG produced in 
J558L cells caused human heavy chain glycosylation to show typical mouse antibody 
glycosylation pattern, hence a species specific cell line will in itself affect the  glycosylation 
[47]. 
Differences in both O- and N-glycosylation in 12 proteins produced by transient transfection 
in CHO and HEK cells have previously been observed, but immunoglobulins were not 
included. A major difference between the proteins from these two cell lines were that the 
majority of proteins expressed in CHO cells had more sialic acid rich glycosylation compared 
to their HEK counterparts. The differences were found to be caused by the choice of cell line, 
and not the culture conditions as they varied only slightly between the two cell lines [48]. 
Sialic acid rich proteins tend to have an extended half-life, as non-sialylated proteins are 
likely to be eliminated quicker as they bind to a liver receptor [49]. In pilot studies, HEK cells 
are often used, and when larger quantities are required, a change to CHO cells often occurs, 
but this transfer may not be as seamless as shown in the study. Whether the glycosylation is 
determined exclusively by cell type or if post-translational changes are equally important, is 
not clear [48]. As the list of these 12 proteins did not include immunoglobulins [48], the 
results can not be directly related to our findings, but we observe with interest the reduced 
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sialic acid content in the HEK produced proteins. As the transiently transfected cell lines 
produced simpler glycoforms as time progressed, possibly because of over-utilization of the 
enzymes required to make the glycoforms, this could indicate that the same occur for IgG1 in 
NS-0 cells, but not J558L cells, as that cell line produced more complex glycoforms. A 
similar observation concerning NS-0 cells was seen with the humanized IgG antibody 
Campath-1H when expressed in three different cell lines as the glycosylation pattern from 
NS-0 showed less complex and less overall glycosylation compared to CHO and Y0 myeloma 
cells [50].  
  Biological activity in the form of complement activation has previously been studied by us 
using the same wild type and mutant molecules as in this report. The main findings in the 
previous report was that IgG3 was more resilient to mutations near the C1q binding site than 
IgG1, as point mutations in IgG3 did not affect ADCML whilst for IgG1 particularly the 
mutant D270A was affected [39]. The difference in ADCML between the mutants could 
possibly be due to glycosylation differences as the mutations introduced are close to the 
glycosylation site. Here we show no striking differences in glycoforms when comparing the 
wild type and mutants and thus the differences in ADCML activity seem only to be due to 
differences in protein structure.  
IgG3 has been showed to possess a stronger ADCC activity compared to IgG1 [51]. As 
ADCC is mainly activated through FcȖRIIIa and removal of fucose caused a 50-fold increase 
in receptor-binding, the dominance of non-fucosylated IgG3 we detected in the present report 
are consistent with IgG3’s stronger ADCC activity [26;51].  
In conclusion, we used a new isolation technique with a high resolution, sensitive LC-ESI-
Orbitrap method for glycosylation profile analysis of human IgG and revealed a striking 
difference between IgG1 and IgG3. IgG1 was mainly fucosylated, while IgG3 was mainly 
non-fucosylated, probably explaining why IgG3 is often better in ADCC activity than IgG1. 
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Furthermore, this difference between IgG1 and IgG3 glycosylation apparently was not due to 
the very large hinge region of IgG3 and mutations near the C1q binding site did not 
significantly influence glycosylation. When employing transiently transfected cell lines to 
produce IgG, the glycosylation structure was more complex earlier in production compared to 
later.    
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Tables 
TABLE 1  
 
Table 1. 18 IgG1 and IgG3 antibodies were analyzed. The first 10 are transiently transfected 
IgG1 and IgG3 antibodies produced in HEK 293E cells harvested at two time points, one 
early (4 days) and one late (10 days). The next 2 antibodies are also produced in transiently 
transfected HEK 293E cells, but there were harvested only once. The last 6 antibodies are 
produced in permanently transfected NS-0 and J558L cells and were harvested only once. 
Leu= leucine, Ala = alanine, Asp = aspartic acid, Pro = proline, His = histidine, Asn = 
asparagine, Arg = arginine 
Antibody Description of mutation Cell line 
IgG1 wt IgG1 wild type HEK 293E 
IgG1 L234A IgG1 where Leu at position 234 is mutated to Ala HEK 293E 
IgG1 L235A IgG1 where Leu at position 235 I smutated to Ala HEK 293E 
IgG1 L234S/L235A IgG1 where Leu at position 234 and 235 is 
mutated to Ala 
HEK 293E 
IgG1 D270A IgG1 where Asp at position 270 is mutated to Ala HEK 293E 
IgG1 P329A IgG1 where Pro at position 329 is mutated to Ala HEK 293E 
IgG3 wt IgG3 wild type HEK 293E 
IgG3 D270A IgG3 where Asp at position 270 is mutated to Ala HEK 293E 
IgG3 P329A IgG3 where Pro at position 329 is mutated to Ala HEK 293E 
IgG3 m15 IgG3 where the hinge is shortened to 15 amino 
acids 
HEK 293E 
IgG1 H435A  IgG1 where His at position 435 is mutated to Ala HEK 293E 
IgG3 N297A IgG3 where Asn at position 297 is mutated Ala HEK 293E 
IgG1 chimeric IgG1 chimeric NS-0 
IgG1 chimeric IgG1 chimeric J558L 
IgG3 wt IgG3 wild type NS-0 
IgG3 m15 chimeric IgG3 where the hinge is shortened to 15 amino 
acids 
NS-0 
IgG3 wt Į-NIP IgG3 wild type  J558L 
IgG3 m15 R435H IgG3 where the hinge is shortened to 15 amino 
acids, and Arg at position 435 is mutated to His 
NS-0 
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TABLE 2 
Table 2. 20 IgG1 and IgG3 glycoforms were searched for and displayed 
below is the mass and charge state 
  
IgG1 
 
IgG3 
 
  Charge state 2 Charge state 3 Charge state 2 Charge state 3  
  EEQYNSTYR 
 
EEQFNSTFR 
G0F 1317.5270 878.6891 1301.5320 868.0235 
G1F 1398.5530 932.7044 1382.5581 922.0411 
G2F 1479.5794 986.7220 1463.5848 976.0587 
G1FS 1544.1007 1029.7362 1528.1058 1019.0729 
G2FS 1625.1271 1083.7538 1609.1322 1073.0905 
G0FN 1419.0663 946.3799 1403.0714 935.7166 
G1FN 1500.0927 1000.3975 1484.0978 989.7342 
G2FN 1581.1191 1054.4151 1565.1242 1043.7518 
G1FNS 1645.6404 1097.4293 1629.6455 1086.7660 
G2FNS 1726.6668 1151.4469 1710.6719 1140.7836 
G0 1244.4976 830.0008 1228.5027 819.3375 
G1 1325.5240 884.0184 1309.5291 873.3551 
G2 1406.5504 938.0360 1390.5555 927.3727 
G1N 1427.0637 951.7115 1411.0688 941.0483 
G0N 1346.0373 897.6939 1330.0420 887.0307 
G2N 1508.0901 1005.7291 1492.0952 1381.2423 
G1S 1471.0717 981.0502 1455.0768 1356.5634 
G2S 1552.0981 1035.0678 1536.1032 1410.5810 
G1NS 1572.6114 1048.7433 1556.6165 1424.2570 
G2NS 1653.6378 1102.7609 1637.6430 1478.2740 
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TABLE 3 
 
Table 3. The average percentage distribution for the different glycoforms found for IgG1 
and IgG3 produced in transiently transfected HEK 293E cells from two harvest, harvest 1 
(early) and harvest 2 (late). The last two IgG antibodies were also produced in HEK 293E 
cells, but these had only one harvest. Of these, IgG3 N297A had no glycoforms, as would 
be expected, as the oligosaccharides are situated at asparagine 297. For all of these 
antibodies, only glycoforms found are presented. 
Glycoforms G0F G1F G2F G1N G1 G2 G0FN G1FN G0 G2FS 
Antibodies from HEK 
293E cells – 2 harvests          
 
IgG1 wt Harvest 1 51.8 45.6 2.7        
IgG1 wt Harvest 2 86.9 13.1         
IgG1 P329A Harvest 1 50.0 45.1 4.9        
IgG1 P329A Harvest 2 81.3 16.6 1.3    0.3 0.1 0.4  
IgG1 D270A Harvest 1 32.8 46.5 14.9    2.2 3.6   
IgG1 D270A Harvest 2 66.1 26.8 2.7 0.5   3.9    
IgG1 L234A Harvest 1 49.3 42.2 8.6        
IgG1 L235A Harvest 2 76.4 20.6 1.9    0.4 0.1 0.6  
IgG1 L235A Harvest 1 49.6 45.2 5.2        
IgG1 L235A Harvest 2 77.7 19.7 1.5    0.4 0.1 0.7  
IgG1 L234A/L235A Harvest 1 41.9 50.9 7.1        
IgG1 L234A/L235A Harvest 2 75.3 22. 2.0    0.1 0.2 0.4  
IgG3wt Harvest 1 0.0    60.4 39.6     
IgG3wt Harvest 2    1.2 85.7 13.1     
IgG3 P329A Harvest 1     44.1 55.9     
IgG3 P329A Harvest 2    1.1 80.0 18.9     
IgG3 D270A Harvest 1  0.3 0.1 0.1 55.0 44.6     
IgG3 D270A Harvest 2    1.6 84.9 13.5     
IgG3 m15 Harvest 1     49.5 50.5     
IgG3 m15 Harvest 2    0.4 82.7 16.9     
           
Antibodies from HEK 293E 
cells -1 harvest          
 
IgG1 H435A HEK 293E 55.8 32.4 9.2     2.0  0.7 
IgG3 N297A HEK 293E           
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TABLE 4 
 
Table 4. The percentage distribution for the different glycoforms 
found for permanently transfected IgG1 and IgG3 from permanently 
transfected cell lines from one harvest only. Only glycoforms that 
were present are presented 
Glycoforms G0F G1F G2F G1 G2 G0 
Permanent cell lines       
IgG1 chimer NS-0 58.1 25.9 11.0 1.0  4.0 
IgG1 chimer J558L 3.2 18.3 71.9 0.9 5.5 0.3 
IgG3 wt NS-0    22.8 77.2  
IgG3 m15 NS-0    23.6 76.4  
IgG3 wt anti-NIP J558L    33.0 67.0  
IgG3 m15 R435H NS-0    21.3 78.7  
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Legends to figures 
 
Figure 1: The 20 different glycoforms studied in this report. Black square = peptide, blue 
square = N-acetylglucosamine, green circle = mannose, red triangle = fucose, yellow circle = 
galactose and pink diamond = sialic acid 
 
Figure 2: The MS spectrum of IgG1 D270A from harvest 1 (early) with relative 
distribution of G0F, G1F, G0FN and G2F. The X-axis shows the mass and the Y-axis 
shows relative rebundance 
 
Figure 3: IgG1 wild type and mutants from transiently transfected HEK 293E cells from 
two harvests, displaying percentage distribution of the 5 glycoforms found for harvest 1 
(early) and 7 glycoforms found for harvest 2 (late). If an antibody did not present a 
particular glycoform, that antibody is not displayed on the graph. 
 
Figure 4: IgG3 wild type and mutants from transiently transfected HEK 293E cells from 
two harvests, displying percentage distribution of the 5 glycoforms found for harvest 1 
(early) and 4 glycoforms found for harvest 2 (late). If an antibody did not present a 
particular glycoform, that antibody is not displayed on the graph. 
 
Figure 5: IgG1 produced in permanently transfected NS-0 and J558L cells from one 
harvest only with the 6 glycoforms found, presented as percentage distribution. If 
anantibody did not present a particular glycoform, that antibody is not displayed on the graph. 
 
Figure 6: IgG3 antibodies produced in permanently and transiently transfected cells. A. 
IgG3 produced in permanently transfected NS-0 and J558L cells from one harvest only with 
the 2 glycoforms found, presented as percentage distribution. B. IgG3 wild type and mutants 
from transiently tranfected HEK 293E cells – harvest 1 (early) and from permanently 
transfected NS-0 and J558 cells. If an antibody did not present a particular glycoform, that 
antibody is not displayed on the graph. 
 
Figure 7: ADCML results for transiently and permanently transfected antibodies. A. 
Transiently transfected IgG1 L234A and IgG1 L235A from both early and late harvest where 
the early harvest is represented by a continuous line and the late harvest by a dotted line. B. 
Transiently transfected IgG1 wild type and IgG1 D270A from two harvests, where the early 
harvest is represented by a continuous line and the late harvest by a dotted line. C. 
Permanently transfected chimeric IgG1 Į-NIP from NS-0 (continuous line) and J558L (dotted 
line) and IgG3 wild type Į-NIP from NS-0 cells (continuous line) and J558L cells (dotted 
line). 
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Figures 
 
FIGURE 1 
 
 
 
FIGURE 2  
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FIGURE 3 
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IgG
1 w
t
IgG
1 L
23
4A
IgG
1 D
27
0A
IgG
1 P
32
9A
IgG
1 L
23
5A
IgG
1 L
23
4A
L2
35
A
IgG
1 w
t
IgG
1 L
23
4A
IgG
1 D
27
0A
IgG
1 P
32
9A
IgG
1 L
23
5A
IgG
1 L
23
4A
L2
35
A
IgG
1 w
t
IgG
1 L
23
4A
IgG
1 D
27
0A
IgG
1 P
32
9A
IgG
1 L
23
5A
IgG
1 L
23
4A
L2
35
A
IgG
1 D
27
0A
IgG
1 D
27
0A
0
20
40
60
80
100
G0F G1F G2F
G0FN G1FN
%
 d
is
tr
ib
ut
io
n 
of
 g
ly
co
fo
rm
s
IgG1 from HEK 293E cells - Harvest 2 (late)
IgG
1 w
t
IgG
1 L
23
4A
IgG
1 D
27
0A
IgG
1 P
32
9A
IgG
1 L
23
5A
IgG
1 L
23
4A
L2
35
A
IgG
1 w
t
IgG
1 L
23
4A
IgG
1 D
27
0A
IgG
1 P
32
9A
IgG
1 L
23
5A
IgG
1 L
23
4A
L2
35
A
IgG
1 L
23
4A
IgG
1 D
27
0A
IgG
1 P
32
9A
IgG
1 L
23
5A
IgG
1 L
23
4A
L2
35
A
IgG
1 D
27
0A
0
20
40
60
80
100 G0F
G1F
G2F
G0FN
%
 d
is
tr
ib
ut
io
n 
of
 g
ly
co
fo
rm
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
FIGURE 4 
IgG3 from HEK 293E cells - Harvest 1 (early)
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FIGURE 5 
 
IgG1 from different
permanently
transfected cell lines
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FIGURE 6 
 
IgG3 from different permanently
 transfected cell lines
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FIGURE 7 
ADCML
Transiently transfected IgG1
Early harvest vs late harvest
2.4
u10
-0
4
4.9
u10
-0
4
9.8
u10
-0
4
2.0
u10
-0
3
3.9
u10
-0
3
7.8
u10
-0
3
0.0
15
62
5
0.0
31
25
0.0
62
5
0.1
25 0.2
5 0.5 1 2
0
20
40
60
80
100
IgG1 L234A, early harvest
IgG1 L235A, early harvest
IgG1 L234A, late harvest
IgG1 L235A, late harvest
Pg/ml
C
yt
ot
ox
ic
 in
de
x 
%
ADCML
Transiently transfected IgG1
Early harvest vs late harvest
2.4
u10
-0
4
4.9
u10
-0
4
9.8
u10
-0
4
2.0
u10
-0
3
3.9
u10
-0
3
7.8
u10
-0
3
0.0
15
62
5
0.0
31
25
0.0
62
5
0.1
25 0.2
5 0.5 1 2
0
20
40
60
80
100
 IgG1 wt, early harvest
 IgG1 D270A, early harvest
 IgG1 wt, late harvest
 IgG1 D270A, late harvest
Pg/ml
C
yt
ot
ox
ic
 in
de
x 
%
ADCML for IgG1 + IgG3
Permanently transfected
NS-O vs J558L cell lines
2.4
u10
-0
4
4.9
u10
-0
4
9.8
u10
-0
4
2.0
u10
-0
3
3.9
u10
-0
3
7.8
u10
-0
3
0.0
15
62
5
0.0
31
25
0.0
62
5
0.1
250.2
5 0.5 1 2
0
20
40
60
80
100
IgG1 ch aNIP-NSO
IgG1 ch aNIP-J558L
IgG3 wt aNIP-NSO
IgG3 wt aNIP-J558L
Pg/ml
C
yt
ot
ox
ic
 in
de
x 
%
A
B
C
 
 
II

 1 
Differences in glycosylation pattern of IgG subclasses induced by 
pneumococcal, meningococcal and two types of influenza vaccines  
A. C. Vestrheim1,2#, A. Moen3, W. Egge-Jacobsen3, L. Reubsaet2, T. Grønhaug Halvorsen2, D. B. 
Bratlie1, B.S. Paulsen2, T. E. Michaelsen1,2# 
1. Department of Bacteriology & Immunology, Norwegian Institute of Public Health, Oslo, Norway 
2. School of Pharmacy, Department of Pharmaceutical Chemistry, University of Oslo, Oslo, Norway  
3. Department of Molecular Biosciences, University of Oslo, Oslo, Norway 
 
Corresponding authors:  
Anne Cathrine Vestrheim 
Norwegian Institute of Public Health 
P.O. BOX 4404 Nydalen, 0403 OSLO 
NORWAY 
 
Tel.: +47 21 07 63 24  
 
Fax: +47 21 07 65 18 
 
Anne.cathrine.vestrheim@fhi.no 
Terje Einar Michaelsen 
Norwegian Institute of Public Health 
P.O. Box 4404 Nydalen, 0403 OSLO 
NORWAY 
Tel.: +47 21 07 63 24  
Fax: +47 21 07 65 18 
t.e.michaelsen@farmasi.uio.no 
 
 2 
Abstract:  
The presence of a carbohydrate moiety on asparagine 297 in the Fc part of the IgG molecule is 
essential for its effector functions and thus its protective effect by vaccination. In order to better 
understand and exploit the protective potential of IgG antibodies, detailed structural carbohydrate 
analysis of vaccine induced IgG’s is therefore of interest. In this report, serum or plasma from 
volunteers receiving vaccines have been collected at different time points and the IgG subclass 
glycosylation pattern determined. The four vaccines used were a pneumococcal capsule 
polysaccharide vaccine, a meningococcal outer membrane vesicle vaccine, a seasonal influenza 
vaccine and a pandemic influenza vaccine. Antibodies against specific vaccine antigens were 
captured using microtiter wells coated with the individual vaccines and analyzed for their 
glycosylation profile by a high resolution, sensitive LC-ESI analysis of trypsin generated glycopeptides. 
Following immunization, the IgG subclass which dominated the response showed an increase in 
galactose and the level of sialic acid levels increased with time for most vaccines. Fucose levels did 
increase for some vaccinees, but for the majority fucose was relatively unaltered. The total 
background IgG glycosylation analyzed in parallel varied little with time, and hence the changes seen 
were caused by immunization. The presence of an adjuvant in the pandemic influenza vaccine 
produced simpler and fewer different glycoforms compared to the seasonal influenza vaccine. This 
pilot study demonstrates that detailed IgG glycosylation pattern analysis might be a necessary step in 
addition to biological testing for optimizing vaccine development and strategies.  
 
 
 
 
 
 
 3 
Introduction: 
A robust IgG response is generally a hallmark of an effective vaccine against invasive 
pathogens(54,57,59). Several studies have demonstrated that the presence of carbohydrates in the 
Fc part of the IgG molecule has a direct influence on effector functions and thus its vaccine protective 
effect. Remarkably, IgG can also have a dramatic anti-inflammatory effect and intravenous 
immunoglobulin G (IVIg), which is pooled immunoglobulin from healthy donors, is used to treat auto-
immune diseases and other chronic inflammatory diseases(35). This anti-inflammatory effect of IVIg 
seems dependent on the presence of sialic acid at the Fc glycosylation site(3). Galactose is another 
carbohydrate of interest, and the amount of antibodies with galactose changes during the life cycle 
and also during disease states, such as Chrohn’s disease or rheumatoid arthritis. Patients suffering 
from these auto-immune diseases display a level of non-galactosylated antibodies that is often twice 
that of what is seen in healthy controls (28). Strikingly, pregnant women suffering from rheumatoid 
arthritis often have an increase in galactose-rich IgG in combination with an improvement of disease 
symptoms (4). Interestingly, mouse IgG1 with high content of galactose has anti-inflammatory 
activity by engaging the inhibitory FcɶRIIb(17), further elucidating the glycan importance for IgG 
function. Fucose on the other hand appears to have an essential role in antibody dependent cellular 
cytotoxicity (ADCC) and opsonophagocytosis as monoclonal humanized IgG1 with low levels of core-
fucose shows dramatic higher ADCC and opsonophagocytosis activity compared to the same 
antibodies with a higher amount of core-fucose (48). This is due to an increased affinity to FcɶRIIIa 
and FcɶRIIIb, respectively(2,13,47). 
Immunization studies have been carried out in mice, where they were immunized with bovine serum 
albumin (BSA), resulting in anti-BSA titres with reduced levels of galactosylation, while increased 
fucosylation were seen after each ovalbumin immunizations(11,21). The glycosylation pattern of 
IgG1following immunization against influenza and tetanus has recently been published, and showed 
that IgG1 had increased level of sialic acid and galactose following immunization, while the 
glycosylation of total background IgG in these volunteers were unaltered (44). Apart from this, we 
 4 
have found no other studies investigating IgG glycosylation pattern in humans following 
immunization. In the spring of 2009, the appearance of a new influenza virus, H1N1, originated in 
Mexico and soon spread throughout the world(5). For the most part, influenza is considered a benign 
illness, but in particularly the elderly, the very young or immune-compromised patients, it can be a 
serious disease, with an increase in morbidity and mortality (18,64). Streptococcus pneumoniae is a 
Gram-Positive diplococcus responsible for a vast array of infectious diseases, including sinusitis, otitis 
media and pneumonia (non-invasive) as well as meningitis and bacteraemia (invasive). It is also the 
main bacteria causing community acquired pneumonia (39). In the very young and in the elderly, the 
bacteria can cause severe morbidity and mortality (55). Meningitidis neisseria is an encapsulated 
gram negative diplococci bacterium that can cause meningococcal disease, where serogroup A, B and 
C account for at least 90 % of all meningococcal disease(51,60).  Meningococcal vaccines mainly 
induced an IgG1 and IgG3 response(32), whilst polysaccharide vaccines, such as pneumococcal 
vaccines, mainly produce an IgG2 response(26). The main IgG subclass for influenza vaccines is likely 
to be IgG1.  
To determine the glycosylation pattern of immunoglobulin G, IgG, from serum or plasma samples, 
mass spectrometry is often used (50,62,63). The carbohydrates are covalently linked at asparagine 
297 on the Fc region of the antibody(4), and the carbohydrates of interest are fucose, sialic acid and 
galactose. In our study, the serum IgG glycosylation pattern of all relevant IgG subclasses from 
volunteers given four different vaccines has been analyzed, a pneumococcal capsule polysaccharide 
vaccine, a meningococcal outer membrane vesicle vaccine, a seasonal influenza vaccine and a 
pandemic influenza vaccine Blood samples were taken at different time points following vaccination, 
and the specific antibodies were captured using microtiter wells coated with vaccine antigens and 
analyzed for differences in glycosylation pattern. For comparison, the glycosylation pattern of total 
background IgG was also analyzed. The presence or absence of different carbohydrates may 
influence the roles of the antibody and its functions. There were 20 glycoforms searched for in this 
report, (See Fig.1). Our method permitted the differentiation of all the IgG subclasses of interest.  
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Methods and Materials: 
Sample collection 
For the pneumococcal and both influenza vaccines, the volunteers involved in the project were set to 
receive these vaccinations as part of their own vaccination regimes, therefore approval from ethical 
committees was not necessary. The plasma and serum from the volunteers receiving the 
meningococcal study were remnants from a previous study that was approved by the Norwegian 
Medicines Control Authority and the Regional Ethical Committee for Medical Sciences, South East 
Norway. A new application for use of these samples in our study was approved by the Regional 
Ethical Committee for Medical Sciences, South East Norway. The vaccine for meningococcal bacteria 
were given as three (or in some cases four) different doses, whilst the other vaccines were given as 
just one dose. Pneumovax® (Sanofi Pasteur MSD) used in this study, is a 23-valent pneumococcal 
polysaccharide vaccine used in adults with little effect in children under the age of 2 years as their 
immune system has not matured enough to start a T-cell independent B-cell response(26,40,55). 
Outer membrane vesicles (OMV) are spherical lipid bilayer vesicle isolated from the outer membrane 
of gram negative bacteria by detergent treatment and centrifugation (8,27,32). An outer membrane 
vesicle vaccine against group B meningococcal (MenBVac®) used in this study has been developed at 
the Norwegian Institute of Public Health in the late eighties (6,14,42).  A vaccine, Pandemrix® (Glaxo-
SmithKline) used in this study was produced, based on strain A/California/7/2009(61). 
IgG subclass determination 
A method to quantitate the subclasses of the meningococcal vaccine response has previously been 
described (32), Shortly, microtiter plates coated with OMV were washed and serum or plasma 
applied together with specific IgG1 and IgG3 antibodies against OMV and incubated for 2 hours at 
37°C, washed and IgG subclass specific monoclonal antibodies were applied. These were obtained 
from the WHO/International Union of Immunological Societies (IUIS) Immunoglobulin Subcommittee, 
IgG1 (HP 6012), IgG2 (HP 6002) and IgG3 (HP 6050)(33).  This was incubated for 1 hour at 37°C, ALP-
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anti-mouse IgG is applied and incubated for 1 hour at 37°C, washed and substrate is applied and the 
plate read in an ELISA reader (Precision microplate reader from Molecular Devices at 405 nm). The 
same principle was applied to detect the influenza and pneumococcal IgG subclass vaccine response, 
but as we had no specific antibodies against the other vaccine antigens, only the amount of one IgG 
subclass compared to another could be measured, not exact ʅg/ml values.  
Antibody capture:  
A microtiter plate was coated with 100 ђl antigen in PBS and left for 48 hours at 4°C. For the 
meningococcal vaccine serum, 4 ђg/ml OMV antigen directed against the Norwegian strain 44/76 
was used. For the pneumococcal vaccine serum, 1 ђg/ml of Pneumovax® pneumococcal capsule 
polysaccharide vaccine (Sanofi Pasteur MSD) was used. For the influenza serum, 1.5 ђg/ml of 
Begrivac® seasonal influenza vaccine (Novartis) and 2 ђg/ml of Pandemrix® pandemic influenza 
vaccine (Glaxo-SmithKline) were used. The plate was then washed x 5 with 300 ђl distilled water. The 
plate was vigorously knocked against the bench to make sure it was empty. A blocking buffer 
consisting of 1 % dried milk in PBS/azid was added to each well- 300 ђl, and incubated for 1 hour at 
37°C. The plate was then washed again with 300 ђl distilled water x 5. The plasma samples were 
diluted 1 to 2.5, and the serum samples 1 in 5 with 5 M NaCl (plasma samples were already diluted 1 
to 1 during the isolation process). This was incubated for 2 hours in 37°C to allow antigen-antibody 
binding. The plate was then emptied, and washed with 300 ђl 1 M NaCl 3 times, and twice with 300 
ђl distilled water. Following the last wash, the plate was knocked vigorously against a bench covered 
in cell paper, to remove any remaining water. The plate was sealed with tape and refrigerated until 
trypsin digestion was started.   
Protein A and Protein G columns were used to isolate background total IgG:  
1 ml HiTrap protein A and 1 ml HiTrap protein G columns from GE Healthcare were coupled together 
with protein A first, followed by the protein G column. By this procedure; IgG1, IgG2 and IgG4 should 
be bound to the protein A column, while IgG3 should be bound to the protein G column. ELISA 
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quantitation was carried out to determine whether the isolation had been successful and only 
negligible traces of IgG3 were found in the eluates from the protein A column (data not shown). 
375 ʅl of serum mixed with 625 ʅl of PBS/azid were added to the columns and left in room 
temperature for 10 minutes. 1 ml of PBS/azid were then injected and left for 10 minutes incubation 
in room temperature. 10 ml of PBS/azid were then eluted through the columns to remove any 
unbound proteins.  
The two columns were then separated and flushed with an additional 5 ml PBS/azid before IgG3 
elution with 0.1 M glycin/HCl (pH 2.8) from the protein G column while IgG1, IgG2 and IgG4 were 
eluted from the protein A column with 0.2 M NaAc (pH 4.0). In total, 5 ml of elution buffer was used 
for each column, giving 5 vials of 1 ml eluate. This was neutralized with 1.5 M TRIS pH 8.5.  
Trypsin digestion before MS analysis 
The background IgG samples were digested with trypsin in Nanosep® Centrifugal Devices (10K, blue, 
OD010C33, Pall Corporation, NY, USA). Approximately 50 ʅg of antibodies were transferred to 
Nanosep devices. The devices were centrifuged for 5 minutes at 13 000xg at 4°C, and the content at 
the bottom of the vial was discarded. 120 ђl Trypsin digestion buffer (50 mM ammonium bicarbonate 
with 15 % acetonitrile) was added to each well or Nanosep® device, incubated for 5 minutes at 80°C 
and sonicated in a water bath for 30 seconds. 600 ng of trypsin was added to each well and 1 ʅg of 
trypsin was added to each centrifugal device (Sequencing grade modified trypsin from Promega 
(V5111) or Roche (11418025001)) and sonicated for 30 seconds in a water bath, followed by an 
overnight incubation at 37°C. The following day the centrifugal devices were centrifuged again at 
13 000 G at 4°C for 5 minutes and the separation filters removed. The content of the wells were 
transferred to Eppendorf tubes (Rainin LiteTouchTM 1.7 ml Microcentrifuge Tube LTT-
170_B(17011862)) and the extracts were dried in a Speedvac centrifuge (Maxi dry Iyo F.D.1.0, Heto-
Holten, Allerød, Denmark) which took approximately 2 hours. 17 ђl of 0.1% formic acid was added to 
each Eppendorf tube or centrifugal device, quickly centrifuged, sonicated for 30 seconds and lastly 
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centrifuged at 16 000 G for 10 minutes at 4°C. 15 ђl was then transferred to MS vials (VWR 
International microvials PP 0.3 ml with short thread, Cat. No 548-0440 and VWR International Screw 
cap PP transparent, 9 mm silic.white/PTFE r, Cat.No. 548-0034), and the tubes were consequently 
stored at -20°C until they were analyzed.  
Mass spectrometry analysis of trypsin digested IgG samples 
The samples were analyzed on a LC-ESI Orbitrap (apart from the samples from one vaccine from the 
pneumococcal vaccine group, details below). LC separation was carried out on Agilent 1200 series 
capillary high-performance liquid chromatography (HPLC).  
6 ђl digestion mixture was injected in to reverse phase (C18) nano online liquid chromatography 
coupled MS/MS analysis, length 150 mm and width 0.075 mm, GlycproSIL C18-80 Å, Glycpromass, 
Stove, Germany. The peptides were eluted in positive ion mode and HCD (higher energy collisional 
dissociation) and CID mode (collision-induced dissociation), where the spectra are isolated and 
detected in a linear ion trap, providing speed and sensitivity. 
Mobile phases were A: water with 0.1 % formic acid and B: acetonitrile with 0.1 % formic acid. LC 
separationwas carried out with a gradient from 10 to 95% and a flow rate of 0.2 ђl/min. 
LC system connected to nanoelectrospray source of Thermo Scientific LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany) operated by Xcalibur 2.0.  
The samples were analysed with higher energy collisional dissociation, HCD, and collision induced 
dissociation, CID. For HCD fragmentation, Orbitrap survey scans were obtained the mass range m/z 
300-2000 and CID fragmentation performed with a target value of 5000 ions. When developing the 
method, samples were run in parallels of three, but as the method was established and reproducible 
results were seen, this was reduced to two parallels for each sample. The majority of the 
meningococcal vaccine response samples were run in parallels of three, while the rest of two.  
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Nanospray ionization was carried out by applying 1.2 kV between 8 ђm diameter emitter (PicoTip 
Emitter, New Objective, Woburn, MA). The capillary temperature was 200°C and capillary voltage 
was 30 V. 
One volunteer from the pneumococcal vaccine group was not run on the Orbitrap mentioned above, 
but on another Orbitrap. This was also a Thermo Scientific LTQ XL mass spectrometer (Thermo Fisher 
Scientific, Bremen, Germany) and the LC separation was carried out on Dionex UltiMate 3000 RCLC 
nano system. 6 ђl digestion mixture was injected in to reverse phase (C18) nano online liquid 
chromatography coupled MS/MS analysis, length 150 mm and width 0,075 mm, Acclaim PepMap C18-
 100Å (Dionex, Thermo Scientific, Sunnyvale CA, USA) with a trap colum, (Acclaim PepMap 100 C18, 5 
ђm, 100 Å, 300 ђm i.d. 5 mm length with a flow of 10 ђl/min). 
Mass spectrometry data analysis 
Mass spectrometric data were analyzed using Thermo Scientific Xcalibur software version 2.0. 
Samples were made in duplicates and the variation measured was calculated.  The mass tolerance of 
the parent ion was set at 5 ppm. The MS peaks from each glycopeptides were extracted as the 
maximum peak height within the same retention time window based on parent ion mass, and the 
MS/MS spectra were manually searched by Qual Browser version 2.0.7. To compare different 
integration methods both the area of the peaks and the average height were tried, but as these gave 
the same results (data not shown), the two methods can be used interchangeably and the average 
height was used in this report. Statistical analysis was carried out using the Friedman test to evaluate 
differences between the visits and the Wilcoxon test to evaluate differences between specific IgG 
and total background IgG, both with a p-value of ख़0.05 considered statistically significant.  
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Results 
4 different types of vaccines were tested, meningococcal (7 vaccinees), pneumococcal (4 vaccinees), 
pandemic influenza 2009-2010 (5 vaccinees) and seasonal influenza 2009-2010 (one vaccinee), 2010-
2011 (two vaccinees) and 2011-2012 (three vaccinees). For the pneumococcal and both types of 
influenza vaccines, three general time points were chosen for blood collection, day 0, right before 
the first vaccine, and day 30 and day 90 after vaccination. Deviations from this did occur to 
accommodate the schedules of the vaccinees. Subclass quantitation confirmed that IgG2 was the 
main subclass response for the pneumococcal vaccine and IgG1 and IgG3 for the others (See Supp. 
Table 1 for meningococcal results, data for the others not shown). It was not possible to obtain 
serum from day 100 from two of the pneumococcal vaccinees, hence day 0, day 14 and day 26 were 
analysed in this case. There was however not much differences between day 14, day 26 and day 112 
and for ease of presentation, the time points for those two vaccinees are still labelled day 30 and day 
90.  Additional time points for some vaccinees were collected. For the 5 vaccinees in the pandemic 
influenza group, three were in the age group 26-30 (vaccinees # 005, # 006 and # 007) and two in the 
age group 65+ (vaccinees # 008 and # 009). These two age groups are not large enough to determine 
statistically significant differences, but can provide indications of trends regarding age differences.  
For the meningococcal vaccinees, the scheme varied somewhat, as these vaccinees had received 
several doses of the vaccine. Plasma samples from seven vaccinees were analysed and the three time 
points used were 1-2 weeks after the third vaccine dose (visit 4), 10-12 months after the third dose 
(visit 6) and finally 1-2 weeks after the fourth dose (visit 7). For vaccinee # 020, serum from three 
earlier time points were also analysed; Day 0 before the first vaccine dose (visit 1), 6-8 weeks after 
the first vaccine dose (visit 2) and 6-8 weeks after the second dose (visit 3). In addition, 8 samples 
from volunteer # 022 were analysed, including the six mentioned, as well as 6-8 weeks after the third 
vaccine dose (visit 5) and 4-6 weeks after the fourth dose (visit 8). The samples taken at all other time 
points than visit 4, 6 and 7 were serum samples, not plasma.  
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The samples studied in this report were all analyzed using LC-ESI Orbitrap, searching for 20 different 
glycoforms (45,63). These include glycoforms with and without fucose, galactose and sialic acid, as 
well as bisecting N-acetylglucosamine (See Fig.1). The glycoforms can be in different charge states 
depending on the number of protons they have, charge state 2 (M+2H)2+, when two protons are 
added, and charge state 3 (M+3H)3+, when three protons are added. Even higher charge states are 
available, but in the experiments reported here, those were the ones found, giving two options for 
each IgG1 or IgG3 glycoform (See Table 1).The peaks were integrated and the values for each 
glycoform in charge state 2 and 3 were combined, and the values for all glycoforms added together, 
and from this the percentage distribution of each glycoform was calculated. MS2 was carried out to 
confirm that the mass belonged to the correct glycoform (See Fig.2). Glycoforms that represented 
less than 1 % of the total distribution were excluded from the graphs. The background IgG was also 
analysed to compare any changes seen in glycosylation. When analysing IgG2 and IgG3 in mass 
spectrometry a differentiation between the two is not possible as the mass of the trypsin generated 
peptides will be the same in both cases. The vaccine serum was separated in to an IgG1/IgG2/IgG4 
fraction by elution from the protein A column, and an IgG3 fraction eluted from the protein G 
column.  
Galactosylation:  
 
The main responding subclass: All vaccines induced an increase in galactose from day 0 to day 30 
after vaccination (See Fig.3 A, D, G and J). At 3 months, galactose levels varied between different 
vaccines and for individual vaccinees. Reactive pneumococcal IgG2 galactose levels increased from 
day 0 to day 30 and then stayed the same or slightly decreased while the galactose levels for 
pandemic IgG1 increased from day 0 to day 30, with a further increase (3 vaccinees) or a decrease (2 
vaccinees) from day 30 to day 100. For the extra pandemic influenza samples, an increase was seen 
at day 290 (vaccinee # 005) and day 559 (vaccinee # 006), both from the younger group, while for 
one vaccinee in the 65+ group, a decrease was seen on day 201. Galactose levels in seasonal 
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influenza IgG1 increased from day 0 to day 30, and kept stabile or decreased from day 30 to day 100. 
Meningococcal IgG1 increased after vaccination (visit 7) and showed diverse level between vaccinees 
after time. Statistical analysis showed statistical significant increases was seen for three of the 
vaccines (See Supp. Table 2), the meningococcal vaccine (p-value 0.005), the seasonal influenza 
vaccine (p-value 0.016) and the pneumococcal vaccine (p-value 0.018). 
The minor responding subclass: Pneumococcal IgG1 and seasonal influenza IgG3 had stable levels of 
galactose (See Table 2).  Pandemic IgG3 showed an increase in galactose for most vaccinees at day 
30, followed by either stabile levels or a further increase at day 100. The same trend regarding the 
late sampling days for IgG1 was seen for IgG3, an increase at day 290 (vaccinee # 005) and day 559 
(vaccinee # 006) and a decrease at day 201 (vaccine # 009). Galactose levels for meningococcal IgG3 
increased after vaccination and decreased with time. No statistical differences were seen for 
galactosylation (See Supp Table 3). 
Fucosylation:  
 
The main responding subclass: Fucose levels increased for the seasonal influenza from day 0 to day 
30, and remained stable or decreased slightly for other vaccines, but fucose levels were overall close 
to or at 100 % fucosylation (See Fig. 3 B, E, H and K). All glycoforms were close to or at 100 % 
fucosylation. No statistical differences were seen for fucosylation (See Supp. Table 2). 
The minor responding subclass: Fucose levels of IgG1 from the pneumooccal vaccine also stay stable 
throughout (See Table 2). Fucose levels in IgG3 for the other 3 vaccines differed between the 
vaccines, with seasonal influenza staying stable, pandemic influenza decreasing and meningococcal 
vaccine increasing. Pneumococcal IgG1 were completely fucosylated while seasonal influenza IgG3 
had one vaccine with stable levels, all the others were non-fucosylated. Pandemic IgG3 fucosylation 
decreased from day 0 to day 30 for almost all vaccinees, and either stayed the same or decreased at 
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day 100. OMV IgG3 decreased at visit 6, followed by an increase at visit 7. Statistical analysis showed 
no significant differences for fucosylation (See Supp. Table 3). 
Sialylation:  
 
The main responding subclass: Sialic acid levels increased from day 0 to day 30 after vaccination for 
all vaccines, and at three months they decreased again for most vaccines (See Fig.3 C, F, I and L). 
Pneumococcal IgG2 sialylation increased from day 0 to day 30, and then stayed stabile. Pandemic 
IgG1 sialylation was more varied, as amongst the 65+ group there was either no sialic acid or a 
decrease on day 30, followed by an increase on day 100. The younger group showed either low 
amounts and a steady decrease throughout, or an increase at day 30 and then a decrease at the next 
time points. For seasonal and meningococcal vaccinees, IgG1 sialylation levels increased after 
vaccination and decreased with time. For the meningococcal vaccinee with 8 visits analysed, the 
amount of sialic acid increased after each vaccination. Statistical analysis showed significant 
increases for three of the vaccines (See Supp. Table 2), the meningococcal vaccine (p-value 0.034), 
the seasonal influenza vaccine (p-value 0.002) and the pneumococcal vaccine (p-value 0.039). 
The minor responding subclass: Pneumococcal IgG1 sialylation stayed stable at 15-20 %, while 
pandemic IgG3 had no sialic acid levels (3 vaccinees) or continuous increases with time (2 vaccinees) 
(See Table 2). Sialylation for seasonal IgG3 stayed stable, while an increase was seen after 
vaccination for meningococcal IgG3, followed by a decrease with time. Sialic acid levels for 
pneumococcal IgG1 did not change very much throughout. IgG3 sialylation levels for the other 
vaccines differed between vaccines, with no change in the seasonal influenza vaccine, increases or 
stable levels at day 30 for the other two, and decreasing or stable levels at day 90. Only the 
meningococcal vaccine showed a statistical significant differences (p-value 0.028) (See Supp. Table 
3). 
Vaccine formulation affects glycosylation of the minor, but not the major responding subclass 
 14 
The pneumococcal vaccine is a carbohydrate vaccine, producing mainly an IgG2 response. The main 
response was rather similar, irrespective of subclass, but the IgG1 minor response from the 
pneumococcal vaccine differed significantly from the IgG1 response from the other vaccines, as 
levels stayed stable for pneumococcal IgG1, but increased in levels for all three carbohydrates (See 
Table 2).    
The adjuvant squalene leads to less complex glycoforms 
Two different types of influenza vaccine were analysed, a seasonal influenza vaccine without 
adjuvant and a pandemic influenza vaccine with the adjuvant squalene. The pandemic influenza 
vaccine induced fewer different glycoforms (4-10 vs 11-13) and these were of a less complex type, 
compared to the adjuvant-free seasonal influenza vaccine (See Fig.4).  The meningococcal vaccine 
had another adjuvant, Al(OH)3, but this did not affect the glycoforms in the same way that squalene 
did for the pandemic influenza vaccine.  
Repeated annual vaccination results in similar glycosylation pattern 
For the seasonal influenza, 3 individuals participated, but two volunteers received the vaccine in two 
or three consecutive years. Hence season 2009-2010 (vaccinee # 010), 2010-2011 (vaccinee # 011) 
and season 2011-2012 (vaccinee # 012) is all the same individual. Season 2010-2011 (vaccinee # 013) 
and 2011-2012 (vaccinee # 014) is the same individual. For the last volunteer, only one season was 
analysed, 2011-2012, from vaccinee # 015. We found that being given the same vaccination for 
consecutive years, the same glycosylation pattern was observed (See Fig.3 G, H and I). 
Differences in glycosylation between individuals 
Variation in glycoforms from one individual to another occurred, but one vaccinee was fairly unique 
compared to the other vaccinees. For meningococcal vaccinee # 022, 8 time points were analyzed, 
and the IgG3 response differed substantially compared to the other meningococcal vaccinees (See 
Fig.5). The IgG3 response was mainly un-fucosylated, but this was apparently specific for that 
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individual, as the total background IgG3 also were mainly non-fucosylated, unlike all the other 
vaccinees, regardless of type of vaccine.   
For seasonal influenza IgG3, all but one vaccinee only had glycoforms with galactose. The same 
vaccinee also portrayed a stabile level with 90 % fucosylated glycoforms, while all other vaccinees 
had no fucosylated glycoforms (See Table 2). This was quite unique compared to the other vaccines, 
as there was no distinct difference between fucosylation of IgG1 and IgG3. For this vaccine, no IgG3 
with sialic acid was observed.  
Glycosylation of background IgG 
The total background IgG did not change significantly from an early time point to a late time point 
after immunization and little difference was seen between IgG1 and IgG3 (vaccinee # 022 being the 
exception), perhaps most surprisingly regarding fucosylation (data not shown). Changes seen in the 
glycosylation pattern for specific IgG were therefore caused by the immunization. When combining 
total background IgG for all four vaccines, total background IgG1 eluted from protein A represented 
54-86 % galactose, 82-99 % fucose and 1-16 % sialic acid. IgG3 eluted from protein G displayed 56-99 
% galactose (excluding pneumococcal vaccinees that had 39-76%), 77-97 % fucose (except two 
meningococcal vaccinees, # 019 and # 022, that portrayed 24-47 % and 2-15 %, respectively) and 0-
31 % sialic acid. Vaccine # 022 showed a large difference in fucosylation between IgG1 and IgG3 (See 
Fig.5). Total background IgG2 from the pneumococcal vaccinees were eluted for protein A; displaying 
46-73 % galactose, 67-96 % fucose and 4-8 % sialic acid. The pandemic influenza vaccine had 2 
vaccinees at 65+ and 3 younger, and the levels of galactose in the 65+ group were 55-58 % for IgG1 
and IgG3, which was distinctly lower than the corresponding values in the younger group; 69-75 %.  
Statistical analysis using the Wilcoxon test with a p-value ख़0.05 considered significant, the main 
responding subclass were compared to the background IgG at day 0 and day 90 for the 
pneumococcal and the two influenza vaccines, and visit 4 and 6 for the meningococcal vaccine. 
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Statistically significant differences were seen for most of the vaccines (See Supp. Table 4). The 
pandemic influenza showed random changes in sialylation following vaccination which was reflected 
in the Wilcoxon test with a p-value of 0.5, and hence not significant. The pneumococcal vaccine 
showed no statistically significant p-values for any types of glycosylation, possibly because the 
second time point was very far apart from the first. 
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Discussion 
The structure of the carbohydrates attached to asparagine 297 in the Fc portion of an IgG molecule 
has direct influence on its effector functions and immune protective capacity. The aim of this pilot 
study was to analyze antibody response after immunization with four different types of vaccines to 
determine the glycosylation pattern. These vaccines were chosen in order to show influence on IgG 
glycosylation by varying the vaccine components by using split, hemagglutinin based influenza 
vaccines, more complex meningococcal outer membrane vesicles (88 % protein, 5 % LPS and 7 % 
phospholipids) with Al(OH)3 as adjuvant and pure pneumococcal capsule polysaccharide. The main 
differences between the pandemic and seasonal influenza vaccines were the dose (3.75 ʅg HA for 
the pandemic and 15 ʅg HA for the seasonal) and adjuvant for the pandemic vaccine only. 
Furthermore, we wanted to investigate variation in IgG glycosylation over time since experiments in 
mice have indicated that especially sialic acid is increasing very late in the immune response, 
compatible with the notion that IgG act anti-inflammatory when the acute risk phase during infection 
is over. Here, mice were pre-sensitized with sheep IgG and challenged with a nephrotoxic serum, 
NTS, giving a mouse IgG response where the level of sialylation for total IgG was reduced by 40 % and 
for specific anti-sheep IgG by 50-60 %(16). It has been suggested that IgG immune response has two 
phases, one pro-inflammatory shown in the acute phase during infection and possibly also right after 
a primary vaccination. A hallmark of such pro-inflammatory IgG activity could be lack of core-fucose, 
favoring ADCC activity and phagocytosis(34,35,46). However, this hypothesis is to a large extent 
based on experiments in mice and not in humans, such as mice being immunized with bovine serum 
albumin (BSA), resulting in anti-BSA titres with reduced levels of galactosylation, while increased 
fucosylation were seen after each ovalbumin immunizations(11,21).  Thus results from human 
immunizations are much needed to clarify if a two-phase biological activity could be observed in a 
vaccination situation in humans. Our present report is a pilot study and the number of subjects 
limited; however, we did observe many striking features which warrant further larger studies. 
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First of all, we did not observe a prominent lack of IgG core-fucose right after vaccination for any of 
the vaccines applied compared to blood samples taken from the same person at later time points. 
Secondly, we did not observe the hallmark for anti-inflammatory IgG; a noticeable increase in 
terminal sialic acid late in the response (up to one year after the primary vaccination) for any of the 
vaccines used. IgG1 responses after influenza and tetanus vaccination have recently been reported, 
displaying the same lack of non-fucose in the beginning and increased sialic acid at later stages 
following vaccination, and instead showed increased galactose and sialic acid shortly after 
vaccination. In that study, two doses of a pandemic influenza vaccine was administered, and serum 
collected 3-5 weeks after each dose showed steady sialic acid levels with time(44). In the present 
report we extend this to IgG3 and IgG2 responses and also include a pure carbohydrate vaccine and a 
complex OMV protein vaccine. We see the same increase in sialic acid shortly after vaccination, but 
at later time points, the values varies from stable (pneumococcal IgG2), a decrease to pre-vaccination 
levels (seasonal influenza IgG1) or increases with booster doses (meningococcal IgG1). We do not 
dispute the presence of two-phase IgG, a pro-inflammatory and an anti-inflammatory, but the basis 
of inducing and balancing these pronounced opposite IgGs seems elusive at least for humans. The 
dependence of these IgG variants upon the glycosylation patterns might also be more complex than 
previously suggested. The anti-inflammatory activity of sialic acid rich human IgG seems well 
documented, although controversial, and a resent paper showed that immune complexes with 
galactose-rich mouse IgG1 asserted anti-inflammatory properties by supporting the association of 
FcɶRIIB with dectin-1 (17,19). This complexity has been shown in mice infected with the yeast 
Cryptococcus neoformans, as administration of monoclonal antibodies lead to acute lethal toxicity 
and cardiovascular collapse when IgG1 was administered due to an increase in platelet activating 
factor, PAF, caused by a complex between C. neoformans glucuronoxylomannan and IgG. The same 
occurrence was not seen with IgG3(23). On the other hand, when mice received IgG1 before a C. 
neoformans infection, pro-inflammatory responses were diminished and granulocyte production 
increased to clear the fungal infection(10). Insufficient amount of antibodies may not cause the 
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desired response, but excessive amounts may be counterproductive, as studies on C. neoformans 
showed interference with oxidative killing when the concentrations of antibodies on the capsule 
surface was too high(53). The same antibody may exhibit both pro- and anti-inflammatory properties 
depending upon the state of infection, type of microbe and the amount of antibody. All these factors 
contribute to a more complex picture than just glycosylation being the foundation of the two-phase 
IgG(7). 
Thirdly, a clear difference was seen between the pro-inflammatory IgG1 and IgG3 subclasses 
following seasonal influenza vaccination as the IgG1 immune response exhibited glycoforms that 
were mainly fucosylated, while the IgG3 glycoforms were mainly non-fucosylated. The total 
background IgG did not portray this pattern and it was therefore a result of the immunization, but 
was seen for this vaccine only. This is the first report on the IgG3 glycoforms after vaccination. We 
have previously studied recombinant chimeric mouse-human IgG3, which we found to be mainly 
non-fucosylated (Vestrheim et al in press). Interestingly, IgG3 antibodies in general appears superior 
to IgG1 regarding capacity for both ADCC and opsonophagocytic activity(2,29). As ADCC is mainly 
activated through FcɶRIIIa, and removal of fucose caused a 50-fold increase in receptor-binding, the 
non-fucosylated IgG3 induced after seasonal influenza vaccination are likely to possess a strong 
capability for ADCC(47). There are several potential explanations for the glycoform differences 
between IgG1 and IgG3, with noteworthy differences in the hinge region structure between IgG1 and 
IgG3 being one of them(15,30). However, no significant glycosylation differences were seen between 
recombinant wild type IgG3 and a hinge truncate mutant of this IgG3, hence the differences seem 
not to be caused by the long hinge region of IgG3 (62 amino acids) relative to the IgG1 hinge region 
(15 amino acids)(31) and Vestrheim et al in press).  
Fourthly, we observed more simple glycoforms by the low antigen dose with squalene adjuvant 
compared to similar high dose, non-adjuvanted seasonal influenza vaccine, but importantly without 
the dominance of non-fucose and non-sialic acid seen in IgG3 from the seasonal influenza (See Fig.4). 
 20 
The seasonal influenza vaccine also caused more diverse glycoforms compared to the pandemic 
vaccine, with 11-13 glycoforms compared to 4-10 glycoforms. Perhaps the low vaccine dose or more 
probably the use of the strongly stimulating squalene adjuvant is having a direct influence on IgG 
glycosylation, as adjuvants are used to enhance the specific immune response against the antigens it 
is inoculated with(20,22,37,38). Possibly this strong immune-stimulation induced by squalene 
enhances the kinetics of the immune response resulting in a less matured IgG glycosylation. Squalene 
has been shown to influence glycosylation, as inhibiting squalene production can improve N-
glycosylation in Congenital disorders of glycosylation(12,58). Interestingly, the meningococcal OMV 
vaccination also included an adjuvant (Al(OH)3), but without the same lack of matured glycoforms as 
for the pandemic influenza vaccination; Al(OH)3 adjuvant being less potent than squalene might be a 
plausible explanation. When the adjuvant MF59, a squalene emulsion,  was used in a previous 
vaccine study with the pandemic influenza vaccine, no differences regarding variety and complexity 
of glycoforms compared to influenza vaccination without adjuvant were noted(36,44).  
Fifthly, there was a considerable variation in glycoforms from one individual to another, indicating 
that glycosylation is a flexible process harboring several parameters which varies among individuals. 
One vaccinee differed strongly from the rest, as meningococcal vaccinee # 022 unlike the others, 
displayed non-fucosylated antigen-specific IgG3 antibodies following vaccination, but as this was also 
reflected in the same individual’s total IgG3, this was a characteristic of the individual, not of the 
vaccine (See Fig.5).  
The IgG subclass dominating the response induced by a polysaccharide vaccine is IgG2(26,40), and 
the IgG2 glycosylation pattern from the pneumococcal vaccine did not differ too much compared to 
the IgG1 dominating the immune response from the other vaccines. The antibody response towards 
polysaccharides differ compared to that against proteins as polysaccharides are generally T-cell 
independent and thus the polysaccharide responding B-cells need less help from T-cells in their 
development towards antibody producing plasma cells. Apparently, such T-cell help towards B-cells 
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has minor influence on the glycosylation pattern of downstream production of IgG from the resulting 
plasma cells. Furthermore, the minor IgG1 subclass response from the pneumococcal vaccine did 
stand out compared to the IgG1 response from the others, as the glycoforms were all fucosylated, 
while galactose and sialic acid levels stayed the same (See Fig.3 and Table 2).  
As glycosylation seems time dependent, the time of an antigenic challenge can therefore be crucial 
to the type of protection offered. Quantifiable IgG titres have been measured between 2 and 4 
weeks after immunization for pneumococcal polysaccharide vaccines, seasonal influenza and 
MenBVac®(24,25,32,49,61). As a measurable antibody response occurs at relatively the same time 
for these vaccines, certain antigens taking longer to trigger an immune response than others are 
therefore not likely to be the reason for glycosylation differences.   
 The antibodies produced following an immunization may kill or otherwise neutralize the pathogens 
by a number of ways such as phagocytosis and serum bactericidal activity (SBA)(1,52), and 
glycosylation can be involved in regulating antibody function(9,41,47,56).  Serum bactericidal activity 
(SBA) and opsonic activity have previously been published for the vaccinees receiving the 
meningococcal vaccine, where reciprocal antibody titres were used to measure the activity(43). For 
SBA, no trends were seen in the glycosylation pattern, but for opsonic activity, three vaccinees 
displayed changes in opsonic activity that could be compared to the glycosylation pattern from these 
two visits(43). Vaccinees # 017 and # 020 showed a large increase in opsonic activity from visit 6 to 
visit 7 with a parallel increase in galactosylation and sialylation for IgG1 and IgG3 antibodies for the 
same visits, (See Table 3), as well as an increase in fucose for IgG3 antibodies. Vaccine # 018 showed 
some increase in opsonophagocytic activity with an increase in sialic acid for both IgG1 and IgG3 (See 
Table 3). While the specific antibody concentration did not change much between these two visits for 
vaccine # 018, a clear increase was seen for both IgG1 and IgG3 in vaccinee # 017 and # 020 (See 
Supp. Table 1).  
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In conclusion, we have analysed serum or plasma from volunteers after immunization with four 
different vaccines and determined that the majority of vaccinees showed distinct increases in IgG 
galactosylation and sialylation following immunization. Changes in IgG fucosylation following 
immunization seemed vaccine dependent and several vaccines resulted in fully fucosylated IgG, while 
seasonal influenza vaccine was the only vaccine resulting in non-fucosylated IgG3. Differences were 
seen in complexity and variability of glycoforms between influenza vaccines with and without 
adjuvant. Glycosylation patterns therefore seem to be affected by both type and intervals of 
immunization, and with further knowledge from larger studies combined with biological data; these 
findings can possibly be used to optimize vaccine formulation and vaccination schedules. 
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Figures 
 
FIGURE 1 
 
 
Figure 1: The 20 different glycoforms studied in this report. Black square = peptide, blue square = N-
acetylglucosamine, green (dark grey) circle = mannose, red triangle = fucose, yellow (light grey) circle 
= galactose and pink diamond = sialic acid. 
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FIGURE 2 
 
 
 
Figure 2: MS2 glycanspecter of an IgG3 molecule, where the peaks for the different carbohydrate 
compositions are shown. Black square = peptide, blue square = GlcNAc, green (dark grey) circle = 
mannose, yellow (light grey) circle = galactose and red triangle = fucose. 
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FIGURE 3 
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 Figure 3: The three main time points for all 4 vaccines presented as percentage distribution of 
galactosylation, fucosylation and sialylation. A, B and C are showing pneumococcal IgG2 while D, E 
and F are showing pandemic influenza IgG1. G, H and I are showing seasonal influenza IgG1 and J, K 
and L are showing meningococcal IgG1. The time points for the meningococcal vaccine were visit 4 
(1-2 weeks after 3rd dose), visit 6 (10-12 months after 3rd dose) and visit 7 (1-2 weeks after 4th dose). 
 
 
 
 32 
FIGURE 4 
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Figure 4: Glyform distribution of specific IgG1 (3 time points) and total background IgG (2 time 
points) for one vaccinee receiving the pandemic influenza vaccine and one vaccinee receiving the 
seasonal influenza vaccine. Glycoforms present at less than 1 % were not included. 
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FIGURE 5 
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Figure 5: Glycoform distribution of IgG1, IgG3 (both 8 time points) and total background IgG (2 time 
points for one vaccine after 4 doses of the meningococcal vaccine. Glycoforms present at less than 1 
% were not included. Visit 1 (Day 0 – 1.dose), visit 2 (6-8 weeks after the 1st dose), visit 3 (6-8 weeks 
after 2nd dose), visit 4 (1-2 weeks after 3rd dose), visit 5 (6-8 weeks after 3rd dose), visit 6 (10-12 
 34 
months after 3rd dose), visit 7 (1-2 weeks after 4th dose) and visit 8 (4-6 weeks after 4th dose). Doses 
were given at visit 1 (1st dose), visit 2 (2nd dose), visit 4 (3rd dose) and visit 6 (4th dose).   
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Tables    
Table 1: Displaying mass to charge (m/z) of 20 IgG1 and IgG3 glycoforms 
 IgG1 IgG3 
 Chargestate 2 Chargestate 3 Chargestate 2 Chargestate 3 
 IgG1 EEQYNSTYR IgG3 EEQFNSTFR 
G0F 1317.5270 878.6891 1301.5320 868.0235 
G1F 1398.5530 932.7044 1382.5581 922.0411 
G2F 1479.5794 986.7220 1463.5848 976.0587 
G1FS 1544.1007 1029.7362 1528.1058 1019.0729 
G2FS 1625.1271 1083.7538 1609.1322 1073.0905 
G0FN 1419.0663 946.3799 1403.0714 935.7166 
G1FN 1500.0927 1000.3975 1584.0978 989.7342 
G2FN 1581.1191 1054.4151 1565.1242 1043.7518 
G1FNS 1645.6404 1097.4293 1629.6455 1086.7660 
G2FNS 1726.6668 1151.4469 1710.6719 1140.7836 
G0 1244.4976 830.0008 1228.5027 819.3375 
G1 1325.5240 884.0184 1309.5291 873.3551 
G2 1406.5504 938.0360 1390.5555 927.3727 
G1N 1427.0637 951.7115 1411.0688 941.0483 
G0N 1346.0373 897.6939 1330.0420 887.0307 
G2N 1508.0901 1005.7291 1492.0952 1381.2423 
G1S 1471.0717 981.0502 1455.0768 1356.5634 
G2S 1552.0981 1035.0678 1536.1032 1410.5810 
G1NS 1572.6114 1048.7433 1556.6165 1424.2570 
 36 
G2NS 1653.6378 1102.7609 1637.6430 1478.2740 
 
 
Table 2: The minor responding subclass from the different vaccines, displayed as increase 
(ј), decrease (љ) or no change (ў) in sugar composition observed at day 30 and day 90 
after immunization, compared to the sample taken before immunization. 
 GALACTOSE FUCOSE SIALIC ACID 
 Day 30 Day 90 Day 30 Day 90 Day 30 Day 90 
Pneumococcal 
vaccine (IgG1) 
ў ў ў ў ў ў 
Pandemic 
influenza 
vaccine (IgG3) 
ј љў љ јљ јў ў 
Seasonal 
influenza 
vaccine (IgG3) 
ў ў ў ў ў ў 
 10-12 
months 
after 3rd 
dose 
1-2 
weeks 
after 4th 
dose 
10-12 
months 
after 3rd 
dose 
1-2 
weeks 
after 4th 
dose 
10-12 
months 
after 3rd 
dose 
1-2 weeks 
after 4th 
dose 
Meningococcal 
vaccine (IgG3) 
љ ј љ ј љ ј 
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Table 3: The 7 meningococcal vaccinees were previously tested for 
serum bactericidal activity and opsonaphagocytic activity. Results are 
shown as reciprocal titres, published previously(43). 
 Serum bactericidal 
activity  
Opsonophagocytic activity 
 Visit 6 Visit 7 Visit 6 Visit 7 
Vaccinee # 016  128 128 128 128 
Vaccinee # 017 ख़2 8 8 64 
Vaccinee # 018 8 8 32 64 
Vaccinee # 019 ख़2 ख़2 ख़2 8 
Vaccinee # 020 2 4 32 64 
Vaccinee # 021 8 2 16 16 
Vaccinee # 022 16 16 16 32 
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Supplementary material 
SUPPLEMENTARY TABLE 1 
Table 1: Specific IgG1 and IgG3 antibodies from meningococcal 
vaccinees, portrayed as ʅg/ml. 
 IgG1 
visit 4 
IgG1 
visit 6 
IgG1 
visit 7 
IgG3 
visit 4 
IgG3 
visit 6 
IgG3 
visit 7 
# 016 15 7.5 6.6 2.3 0 2.0 
# 017 11.3 0.9 3.8 3.4 0 5.2 
# 018 26.3 5.6 6.3 5.2 0 0.9 
# 019 2.6 1.3 1.6 0.8 0.2 0.4 
# 020 21.3 5.6 9.8 7.8 0 4.7 
# 021 22.5 5.6 7.0 3.8 0 7.5 
# 022 15 5.6 6.5 1.1 0 5.6 
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SUPPLEMENTARY TABLE 2 
        
 Table 2: Statistical analysis using the Friedman test for all vaccines for the main responding 
subclass. P-values of <0.05 were considered significant and are marked in bold. 
MEDIAN P-value 
  
SPECIFIC IgG1 response  
  
TOTAL IgG1  
Prot A  Specific Total Prot A 
Meningococcal 
vaccine Visit 4 Visit 6 Visit 7 Visit 4 Visit 6 
Galactosylation 75 84.1 83.3 74.3 71.2 0.005 0.059 
Fucosylation 100 100 100 93.4 95.8 0.368 0.705 
Sialic acid 25.6 11.4 29.6 3.7 3.5 0.034 0.705 
   
MEDIAN P-value 
  
SPECIFIC response  
  
TOTAL IgG Prot 
A  Specific Total Prot A 
Pandemic flu 
vaccination(IgG1) Day 0 Day 30 Day 90 Day 0 Day 90 
Galactosylation 73.5 84.1 87.9 69 68.6 0.074 1 
Fucosylation 100 94.7 93.2 92.7 89.4 0.097 0.655 
Sialic acid 5 10.8 15.3 8.6 7.8 0.779 0.655 
Seasonal flu 
vaccine (IgG1)         
Galactosylation 85.05 88.8 85.5 61.85 64.24 0.016 0.014  
Fucosylation 89.6 90.35 89.8 94.39 93.9 0.607 0.102  
Sialic Acid 12.75 17.95 15.15 6.05 6.9 0.002 1  
Pneumococcal 
vaccine (IgG2)         
Galactosylation 67.4 83.3 80.55 62.2 64.85 0.018 1  
Fucosylation 97.45 99.0 97.95 92.75 92.1 0.105 0.317  
Sialylation 17.95 29.1 27.35 5.85 7.85 0.039 0.317  
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SUPPLEMENTARY TABLE 3 
 
 Table 3: Statistical analysis using the Friedman test for all vaccines for the minor responding 
subclass. P-values of <0.05 were considered significant and are marked in bold. 
MEDIAN P-value 
SPECIFIC IgG3 response 
 
TOTAL IgG3 
Prot G Specific Total Prot G 
Meningococcal vaccine Visit 4 Visit 6 Visit 7 Visit 4 Visit 6 
Galactosylation 77.8 71.1 85 76.3 79.9 0.565 0.257 
Fucosylation 190.6 74.4 85.9 84.4 86.5 0.18 0.705 
Sialic acid 23.6 4 23.4 15.9 17.8 0.028 0.705 
   
MEDIAN P-value 
SPECIFIC response 
TOTAL 
IgGProtein  G Specific Total Prot A 
Pandemic flu 
vaccination(IgG3) Day 0 Day 30 Day 90 Day 0 Day 90 
Galactosylation 66.3 66.7 57.4 67.1 67.5 0.368 0.655 
Fucosylation 96.5 54.7 76 85.9 87.5 0.05 0.18 
Sialic acid 0 0 0 17.4 17.8 0.905 0.655 
Seasonal flu vaccine 
(IgG3)         
Galactosylation 100 100 100 63.75 67.3 0.368 1  
Fucosylation 0 0 0 93 93.65 0.368 0.414  
Sialic Acid 0 0 0 17.65 16.2 X 1  
Pneumococcal vaccine 
(IgG1)    
TOTAL IgG1 
Protein A    
Galactosylation 85 88.5 87.65 70.05 61.15 0.627 0.317  
Fucosylation 100 9100 100 93.8 96.45 0.368 0.317  
Sialylation 14.45 15.15 16.9 10.1 9 0.717 0.317  
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SUPPLEMENTARY TABLE 4 
 
Table 4:  Statistical analysis of specific IgG versus total background Wilcoxon. P-values of <0.05 were 
considered significant and are marked in bold. 
 Wilcoxon test Pneumo - Prot A Pandemic - prot A Seasonal - prot A Meningo - prot A 
  Day 0 Day 90 Day 0 Day 90 Day 0 Day 90 Visit 4 Visit 6 
Galactosylation 0.465 0.068 0.5 0.043 0.028 0.028 0.499 0.018 
Fucosylation 0.465 0.465 0.043 0.043 0.173 0.028 0.018 0.018 
Sialylation 0.068 0.068 0.684 0.5 0.028 0.046 0.018 0.018 
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